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Resumo 
A diabetes tipo 2 (DT2) afeta mais de 300 milhões de pessoas em todo o mundo, 
causando complicações severas e morte prematura. Contudo, os mecanismos 
moleculares associados a esta doença são, atualmente, pouco conhecidos. DT2 é 
caracterizada, em parte, pela disfunção de ilhotas endócrinas pancreáticas, não 
havendo produção suficiente de insulina. Os recentes avanços em estudos de 
associação em larga escala genómica têm demonstrado uma clara associação 
entre polimorfismos de um só nucleótido (PSN) e D2T. Uma grande parte destas 
variantes estão localizadas em sequências não codificantes que coincidem com 
marcas epigenéticas de potenciadores e de sítios de ligação de fatores de 
transcrição essenciais para uma boa função e organização das ilhotas endócrinas. 
Os potenciadores são sequências não-codificantes que regulam a expressão dos 
seus genes-alvo, interagindo com os promotores em cis. A hipótese do presente 
projeto científico é demonstrar que os PSNs associados a D2T podem afetar os 
sítios de ligação dos fatores de transcrição e consequentemente, a atividade das 
sequências regulatórias potenciadoras, traduzindo-se em diferenças 
transcricionais do gene. A primeira abordagem para testar a hipótese centralizou-
se em ensaios de transgénese em peixe-zebra. Cinco das dez sequências testadas 
foram consideradas potenciadoras em pâncreas endócrino. A segunda 
abordagem baseou-se no impacto das variantes nas sequências potenciadoras. 
Numa sequência, a atividade potenciadora foi afetada pela presença de uma 
variante num sítio de ligação de PDX1, um fator de transcrição importante no 
desenvolvimento do pâncreas.  Como perspetivas futuras, irão ser testadas as 
sequências em células β humanas em cultura e identificar-se-ão os genes-alvo 
das sequências, por 4C, captura de conformação cromossómica circularizada. 
Este trabalho ajudará a compreender melhor a importância da presença de 
variantes em genoma não-codificante no desenvolvimento de DT2. 
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Abstract     
Type 2 diabetes (T2D) affects over 300 million people, causing severe 
complications and premature death, yet the underlying molecular mechanisms 
are largely unknown. This condition is partially characterized by endocrine 
pancreatic islet dysfunction, leading to insufficient insulin production. By now, 
genome-wide association studies have shown that some single nucleotide 
polymorphisms (SNPs) are associated to T2D. Part of these variants are located 
in non-coding sequences with marks for enhancer activity, and some of them 
overlap with binding sites of transcription factors (TFs) known to be required for 
proper endocrine pancreas function. Enhancers are non-coding sequences that 
regulate the expression of their target genes by interacting with their promoters 
in cis. Our working hypothesis is that T2D associated SNPs might impair TF 
binding, affecting the enhancer activity of the sequence, ultimately translating 
into transcriptional changes of the downstream genes. At first, to approach this 
hypothesis, we have performed in vivo transgenesis assays in zebrafish to test if 
sequences overlapping with T2D associated loci were enhancers. We found that 
five out of ten tested sequences are endocrine pancreas enhancers. Secondly, we 
analyzed the impact of the risk associated variant in the enhancer activity. We 
found that in one out of three sequences, the enhancer activity was disrupted by 
the presence of a single nucleotide modification in a putative binding site for 
PDX1, an important transcription factor in pancreas development. We further 
analyzed this sequence by dividing it in fragments, testing them for endocrine 
enhancer activity. These results lead us to conclude that most likely the loss of 
the PDX1 binding site is accompanied by the gain of a repressor binding site that 
might contribute to the inactivation of the tested enhancer. As future approaches, 
we will test the enhancer activity of the selected sequences in human beta cell 
lines and perform Circularized Chromosome Conformation Capture (4C-seq) to 
identify the enhancer’s target genes. Overall this project will help to better 
understand the importance of non-coding variants in the development of T2D. 
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I. Introduction 
1. Eucaryotic transcription and cis-regulatory elements 
Eukaryotic transcription is an important process in which a RNA molecule is 
synthetized using DNA as template, in order to carry the information transcribed outside the 
cell nucleus (Hahn, 2004). Outside of the nucleus, the newly synthetized molecule, 
messenger RNA (mRNA), is translated into proteins, essential to cellular viability and 
function. All the cellular biological processes require a spatial and temporal regulation of 
gene expression and one of the key players for a proper protein-coding genes transcription 
is RNA polymerase II (Pol II), an enzyme that synthesizes mRNA (Butler & Kadonaga, 
2002; Hahn, 2004), dependent from other DNA-specific-binding proteins (Trans-regulatory 
elements). These trans-regulatory elements bind to the promoter region and to cis-regulatory 
elements (CREs) of DNA, able to interact to each other by chromatin loops ( Butler & 
Kadonaga, 2002; Hahn, 2004 ; Levine et al., 2014) and allowing the Pol II activity.   
The promoter region is responsible for the transcription initiation, by Pol II (Juven-
Gershon & Kadonaga, 2010). The core promoter allows the preinitiation complex formation 
(PIC) (Maston et al., 2006), being a decisive target, near the transcription start site (TSS) 
containing the TATA box, initiator element, downstream promoter element and motif ten 
element (Maston et al., 2006). These elements recruit the general transcription factors (GTF) 
for the PIC formation (Butler & Kadonaga, 2002; Frith et al., 2008; Lim et al., 2004). The 
proximal promoter is upstream of the core promoter and contains binding sites required for 
activators to initiate the gene transcription (Butler & Kadonaga, 2002; Maston et al., 2006). 
An important transcriptional activator is the mediator complex, which forms larger 
complexes with other structural proteins as cohesins (Poss et al., 2013), allowing the 
interaction between the promoter and enhancers by chromatin loops (Kagey et al., 2011).   
At the promoter region, the eukaryotic transcription mediated by Pol II includes three 
phases: initiation, elongation and termination (Nechaev & Adelman, 2012). 
Transcription is started when the initiation complex is recruited to the promoter 
region (Nechaev & Adelman, 2012). The GTFs, transcription factor (TF) IIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH, bind to the core promoter and the PIC is formed (Cosma, 2002; 
Hahn, 2004). The binding of TFs will allow changes in the chromatin state. When PIC is 
2 
 
formed, Pol II is recruited to TSS and mRNA synthesis begins (Hahn, 2004; Hampsey, 1998; 
Lee & Young, 2000 (Butler & Kadonaga, 2002).  
 After transcription initiation, most of the GTFs are released (Kaphingst et al.,2010) 
and the elongation factors are recruited. Pol II will add to the 3`end of the nascent mRNA 
one nucleotide at a time until the termination factors bind to the transcription complex. Then, 
Pol II is released and mRNA is processed (Hirose & Ohkuma, 2007; Ni et al., 2004). 
Although transcription is mostly centered at the promoter, promoters do not contain all the 
information required for the proper spatial and temporal regulation of transcription, being 
part of this information present in CREs. CREs are DNA sequences that contain specific 
recognition sites for TFs, repressing or enhancing the transcription of one specific gene,  
controlling gene expression (Butler & Kadonaga, 2002; Maston et al., 2006; Shibata et al., 
2015). In addition, epigenetic modifications that alter  chromatin structure, also contribute 
to gene transcriptional regulation, increasing its complexity (Müller & Stelling, 2009).     
There are two types of CREs, the proximal and the distal. The proximal CREs are 
composed by promoters and their proximal regulatory elements. The distal CREs includes  
enhancers, silencers and insulators  (Fig.1) (Bulger & Groudine, 1999; Maston et al., 2006; 
reviewed in Blackwood & Kadonaga, 2016). 
 CREs sequences can act long range, being located hundreds of kilobases (kb) away 
from the promoters that they interact with (Butler & Kadonaga, 2002).  
Silencers are distal target binding sequences for trans-acting repressors resulting in 
transcription repression (Maston et al., 2006; Chen & Widom, 2005; Harris et al., 2005). 
Silencers can remodel chromatin (Heinzel et al., 1997) interfering with PIC assembly 
(Maston et al., 2006). 
Insulators are boundary elements that block the action of neighbor regulatory 
elements of a specific gene, preventing the activation of the incorrect gene, often limiting 
regulatory landscapes.(Butler & Kadonaga, 2002; Maston et al., 2006). Insulators can disrupt 
enhancer-promoter interactions, inhibiting chromatin loops as described by Ali and and co-
workers ( 2016). Besides enhancer blocking, they can act as a heterochromatin barriers, 
preventing a transcriptionally active euchromatin turn into inactive heterochromatin 
(Mutskov et al., 2002).    
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Figure 1. Representative gene regulatory region (Maston et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
The human genome is composed by coding and non-coding DNA, both crucial to a 
proper function of cells and tissues. It is estimated that only 2% of the human genome 
corresponds to protein-coding regions, while 43% are transcribed non-coding regions and 
55% are untranscribed regions (Fig. 2). The non-coding regions of the genome comprises 
CREs, contributing to several arrangements in transcriptional regulation, increasing the 
number and complexity of expression patterns. This complexity in expression patterns is an 
important factor in the appearance of new cellular functions (Barrett et al., 2012). This is one 
of the current explanations to why the increase of the complexity of organisms is 
accompanied by a lower protein-coding per DNA ratio (Shabalina & Spiridonov, 2004). 
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Figure 2.  Proportions of the coding and non-coding sequences in the human genome (Shabalina & Spiridonov, 2004) 
 
 
 
 
 
 
  
1.1.Enhancers   
 Enhancers are CREs that can increase the transcription level of a specific or a set of 
genes (Istrail & Davidson, 2005; Maston et al., 2006). They can be located downstream, 
upstream or within introns and exons of their target genes (Maston et al., 2006; Pennacchio 
et al., 2013). Their function is independent of their distance and/or orientation to the target 
gene, being difficult to predict which gene is controlled by an enhancer simply by sequence 
analysis (Atchison, 1988). 
 Enhancers contain specific transcription factors binding sites (TFBS) that interact 
cooperatively, recruiting co-activators and co-repressors, activating the promoter of the 
target gene (Maston et al., 2006; Mora et al., 2015). Different combinations of TFs determine 
the specificity of the enhancer. Additionally, different specific tissue enhancers can interact 
with the same gene promoter, composing the expression pattern of the gene. (Remenyi et al., 
2004¸  Delic et al., 1991).  
Being an important and fundamental DNA regulatory sequence, whose activity 
defines specific timings and locations for the transcriptional activity of genes,  enhancers 
have arisen as elements of great potential and interest, being one of the best functional 
elements of the non-coding part of DNA described (Narlikar & Ovcharenko, 2009; 
Pennacchio et al., 2013). Currently, there are more than 80,000 putative enhancers identified 
in the human genome, using several genome-wide approaches and different techniques such 
as DNase I hypersensitivity, TFBS and chromatin marks assessment (Coppola et al., 2016).   
 One example of a long-range enhancer is the ZRS enhancer in the LMBR1 gene that 
controls besides LMBR1, SHH, at one megabase (Mb) of distance from its promoter. SHH is 
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expressed during limbs development, in the zone of polarizing activity. This specific zone is 
required for pattering and development of limbs. When ZRS presents single nucleotide 
variations, it acquires a gain of function, causing an ectopic expression of SHH, which leads 
to a congenital disease characterized by additional digits (preaxial polydactyl) (Lettice et al., 
2002). This is also an excellent example showing that single nucleotide variations in 
regulatory elements might cause congenital abnormalities. (Lettice et al., 2002; Lettice et al., 
2003) (Fig.4 - Andrey et al., 2017).  
How enhancers can act at long range is poorly understood, however the most 
prevalent hypothesis is that enhancers can be placed near the promoter of their target genes 
by chromatin loops (Pennacchio et al., 2013; Vilar & Saiz, 2005; Andersson et al.,2015) (Fig 
3).  
 
 
 
    
 
 
 
 
  
 This was originally described in Escherichia coli (E.Coli) lactose operon, which is 
a regulatory bacterial element. In this particular case, a repressor binds in two loci by 
chromatin looping, blocking Pol II assessment in the DNA sequence and consequently the 
transcription (Mandal et al., 1990).     
The chromatin loop theory settles in two main evidences. The first evidence came 
from techniques based on chromosome conformation capture (3C) (Dekker et al, 2002; 
(Kadauke & Blobel, 2009). This methodology is applied to determine the spatial 
organization of chromatin in a cell. Cells are fixed with formaldehyde, maintaining their 
 
A 
B 
Figure 3 – The promoter-enhancer interaction regulates the gene expression. A. When physically distant, the promoter has 
no possibility to interact with the enhancer, resulting in a silent mode of gene expression; B. After a stimulus, the chromatin 
reorganizes and allows the interaction between promoter and enhancer, by proximity, by chromatin loops. Adapted from 
Andersson et al., 2015.    
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nuclear structure, including physical interactions of genomic loci. DNA is cut by restriction 
enzymes and subsequently re-ligated. Fragments that are in the three-dimensional 
arrangement of the nucleus, close together, will be more frequently ligated, in contrast to 
fragments that remain faraway. Therefore, the distance of two loci, in the 3D distribution of 
DNA in the nucleous might be calculated by PCR based techniques. Two loci that are 
together in the 3D space will have a higher probability to be ligated and therefore will 
generate a higher PCR product when using quantitative PCR primers for these genomic 
locations (Kadauke & Blobel, 2009). There are other varieties that use next generation 
sequencing (NGS): 4C and 5C (Dostie et al., 2006; Simonis et al., 2006).  The second 
evidence is based on the close proximity of enhancer and promoter regions in the cell 
nucleus, visualized by fluorescence in situ hybridization (FISH) (Pennacchio et al., 2013). 
This technique relies in probes against primary transcripts or DNA, detecting the proximal 
association of genomic regions (Kadauke & Blobel, 2009).   
 
1.1.1. Enhancers identification and prediction 
 One of the main challenges of the enhancers study is their identification in the 
genome. NGS allied to computational biology has emerged as a good strategy, in part, to 
overcome this challenge (Pennacchio et al., 2013; Wang et al., 2013). Several approaches, 
such as chromatin immunoprecipitation (ChIP), DNaseI-digested chromatin (DNase 
hypersensitivity) and Formaldehyde-assisted isolation of regulatory elements (FAIRE) 
followed by NGS are now used as enhancer prediction tools (Bu et al., 2017).   
Alternatively, enhancer identification can be performed based on comparative 
genomics by phylogenetic footprintings, exploring the fact that some non-coding enhancers 
are highly conserved between different species (Zhang & Gerstein, 2003). This strategy 
assumes that sequence conservation is an indicator of DNA functionality, therefore, 
conserved non-coding sequences are good candidates to be functional enhancers. 
Additionally, sequence conservation might help to identify functional orthologous 
enhancers, shedding light on the molecular mechanisms that might operate in these 
sequences. (Chatterjee et al.,2011; Fisher et al., 2006; Hare et al., 2008; McGaughey et 
al.,2009; Swanson et al., 2011).  
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 Other approaches to identify enhancers must be explored, since not all enhancers 
show a high degree of sequence conservation among divergent species (Yang et al., 2015). 
Recently, it has been shown that specific chromatin epigenetic marks have been associated 
to enhancers, proving that chromatin signatures can be specific identifiers of enhancers. 
Thus, the epigenetic marks can be used as a great tool for prediction of these regulatory 
elements  of the transcription in the human genome (Heintzman et al., 2007). 
The epigenetic marks used to recognize a putative enhancer (Fig.4) are histone H3 
acetylated at lysine 27 (H3K27ac) (Creyghton et al., 2010) and histone H3 monomethylated 
at lysine 4 (H3K4me1) (Heintzman et al., 2007). H3K4me1 is present in active and primed 
enhancers, allowing to distinguish enhancers and promoters (Heintzman et al., 2009). In 
contrast, H3K27ac is present when the enhancer is active, making the distinction between 
active and primed enhancers  (Creyghton et al., 2010; Heintzman et al., 2009; Rada-Iglesias, 
2018). The ENCODE project (Dunham et al., 2012), a consortium of many laboratories 
worldwide has described chromatin epigenetic marks in several tissues and cells lines 
genome wide. The available data from ENCODE have been extensively explained to predict 
regulatory functional elements, such as enhancers (Rosenbloom et al., 2012).  
 
 
 
 
 
 
One of the first associations between H3K4me1 and H3K27ac and enhancers was 
done by ChIP (Heintzman et al., 2007). ChIP is a technique based on crosslinking of DNA 
and proteins, followed by a specific antibody enrichment for a DNA-binding protein. The 
resultant DNA fragments are sequenced by NGS, being possible the identification of putative 
enhancers and TFs that might bind with enhancers, genome wide (Cuddapah et al., 2009; 
Hubner & Spector, 2010; Robertson et al., 2008; Robertson et al., 2007; Valouev et al., 
2008). Additionally, Heintzman and colleagues have shown that sequences enriched for 
Figure 4 – ZRS enhancer in Lmbr1 locus. H3K27ac and H3K4me1 epigenetic marks profile showing a peak in enhancer 
locus. (Andrey et al., 2017).  
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H3K4me1 and H3K27ac function as enhancers, when tested for enhancer activity by reporter 
assays (Heintzman et al., 2007).  
Besides addressing epigenetic marks, there are chromatin regions that are DNase I 
hypersensitive, that can also be an alternative strategy to identify enhancers (Dorschner et 
al., 2004). DNase I hypersensitivity assessment is based on the property of active CREs to 
be hypersensitive to cleavage by the endonuclease DNase I (Sullivan et al., 2015).  
Another approach to predict enhancers is FAIRE. FAIRE, similar to  DNA I 
hypersensitivity, detects open chromatin sites.(Song et al., 2011). This technique is based in 
biochemical differences between nucleosome bound DNA and nucleosome free DNA. Cells 
are crosslinked with formaldehyde, then they are lysed, sonicated and it is performed a 
phenol-chlorophorm DNA extraction. Crosslinking will fix DNA to nucleosomes, allowing 
that during phenol-chlorophorm DNA extraction, nucleosome bound and nucleosome free 
DNA will have different affinities to organic and aqueous phases, respectively (Giresi et 
al.,2007).  
2. The vertebrate pancreas 
The vertebrate pancreas forms from two different primordia from the foregut 
endoderm, the dorsal and the ventral bud (Pan & Brissova, 2016).  The pancreas is 
constituted by an endocrine and exocrine/acinar component, having important roles in 
digestion and metabolism (Jennings et al., 2015). The endocrine compartment comprehends 
the hormone-expressing-cells (islets of Langerhans). These hormones are responsible for 
maintaining glucose homeostasis, controlling carbohydrate, lipid and protein metabolism. 
The exocrine compartment has a gastrointestinal function, containing digestive enzymes 
expressing-cells, that aid digestion by secreting these enzymes into the digestive tract 
(Habener et al., 2005; Jennings et al., 2015).     
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2.1.The endocrine pancreatic islet – islet of Langerhans  
 
The endocrine pancreas is composed by small islets of hormone-expressing-cells 
scattered in the acinar tissue (Jennings et al., 2015). These hormone-expressing-cells are beta 
(β), alpha (α), epsilon (𝜀), delta (δ) and pancreatic polypeptide (PP) cells. β-cells produce 
insulin. α-cells are responsible for glucagon secretion and 𝜀 – cells ghrelin. Finally, the δ-
cells secrets somatostatin and  PP- cells pancreatic polypeptides (Sussel & Mastraci, 2013).  
 Each of these type of endocrine cells has its own precursor cell, that express a specific 
combination of TFs  (Herrera et al., 2002) and their differentiation occurs during 
embryogenesis (Kulkarni, 2004).    
2.2.Vertebrate pancreas development and transcriptional networks  
 
 Most of the knowledge about vertebrate pancreas development has been reached by 
knockout studies in mice, disrupting transcription factors involved in endocrine and exocrine 
pancreas formation (Habener et al., 2005) (Table 1).  
 
 Table 1.  TFs knockout studies in mice showing consequences in pancreas development (Ahlgren et al,  1996; Ahlgren et 
al., 1998; Gittes et al., 1996; Lee et al., 1995; Naya et al., 1997; Murtaugh & Melton, 2003; Gu et al., 2011) 
 
Transcription factor disrupted Consequences 
(Insulin promoter factor) PDX1 Pancreas agenesis 
(Insulin gene enhancer protein) ISL-1 Death; lack of exocrine and islet cells differentiation 
(NK2 homeobox 2 protein) NKX2.2 β-cells absence and α-cells reduction 
(NK6 homeobox 2 protein) NKX6.1 β-cells inhibition 
(Neuronal differentiation 1 protein) NEUROD1 Immature β-cells  
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During pancreas development, neurogenin 3 (NGN3) determines endocrine and 
exocrine fate, being expressed in a biphasic way in two different temporal waves of 
embryonic endocrine differentiation. In the first period of NGN3 expression (Fig.5 - A) 
occurs the primary transition of endocrine lineage and the second period of expression 
initiates right before the second wave (Fig.5 – B). The regulation of these levels is complex 
and not well established. However, currently, it is believed that the emerging expression of 
neurogenin 3 (NGN3) in bipotent progenitors (Fig.5-B) in the pancreatic epithelium inhibits 
Notch signaling and determines the fate of these cells as endocrine pancreas (Pan & 
Brissova, 2016; Habener et al., 2005; Murtaugh & Melton, 2003), while (Pan & Brissova, 
2016; Habener et al., 2005; Murtaugh & Melton, 2003) high Notch signaling, in part, 
mediated by SRY-Box 9 (SOX9) and hepatocyte nuclear factor 1β (HNF1β) will determine 
a exocrine pancreas fate. (Bastidas-Ponce et al., 2017).   
Two of the principal TF involved in endocrine pancreas development are homeobox 
protein ARX (ARX) and paired box protein 4 (PAX4). They start being co-expressed in 
NGN3 positive cells being more specific through its differential expression, during 
Figure 5 – Genetic lineage networks of pancreas development.  (Adapted from Bastidas-Ponce et al., 2017) 
A 
B 
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endocrine cells development. Cells that express a higher level of PAX4 will differentiate 
into β and δ-cells. In the other hand, the cells that express higher levels of ARX will be 
differentiated into α-cells (Bastidas-Ponce et al., 2017; Collombat, 2005).  
The differentiation of α-cells will rely in multipotent pancreatic progenitor cells that 
express important TFs such as paired box protein 6 (PAX6), regulatory factor X6 (RFX6), 
POU Class 3 Homeobox 4 (POU3F4), hepatocyte nuclear factor 3-beta (FOXA2) and TF 
MafB (MAFB) (reviewed in Bramswig and Kaestner, 2011). For β-cell differentiation, 
PDX1 and NKX6.1 are the most important TF involved. They have as a direct target the 
INSULIN gene, being important not only for β-cell differentiation but also for a proper β-
cell function (Ahlgren et al., 1996).  
In NGN3 positive cells, NKX2.2 represses NEUROD, a TF present in pancreatic 
progenitor cells, generating α-cells and activates NEUROD to give rise to β-cells (Mastracci 
et al., 2013) .  
Cell differentiation is followed by a functional maturation step, where cells acquire 
their function, the responsiveness to glucose. The two main required TFs for α and β-cells 
maturation are MAFA and MAFB. TF MafA (MAFA) expression is regulated by β-cells 
specific TFs NEUROD1, NKX6.1,NKX2.2, FOXA2, PAX6, RFX6 and GLIS Family Zinc 
Finger 3 (GLIS3) (Arda, Benitez, & Kim, 2013). This cluster of TFs together with PDX1 
regulates the expression of INSULIN (Palanker et al., 2006; Taylor et al., 2013; Zhang et al., 
2005).  
After β-cells maturation, cells synthetize and secret insulin in response to glucose 
levels in blood plasma (Kulkarni, 2004). Insulin is a hypoglycemic agent, having the 
capacity to lower blood glucose levels, while glucagon counteracts the insulin action, 
stimulating glycogenolysis and gluconeogenesis (Jennings et al., 2015).  
3. Cis-regulation and diseases  
The sequencing of  human genome has demonstrated that approximately 98% of total 
non-coding DNA presents marks for enhancer activity, suggesting that many of these 
sequences might be enhancers (Edalat, 2012; Hindorff et al., 2009; Pennacchio et al., 2013; 
Venter et al., 2009). It is reasonable to believe that variations in the sequences of these 
regulatory elements can result in transcriptional dysregulation of genes, phenotypic 
alterations and disease (Maston et al., 2006; Pennacchio et al., 2013). One example is the 
12 
 
translocation in β-GLOBIN gene, with consequential thalassemias (Kleinjan & Coutinho., 
2009). Thalassemias are caused by a disequilibrium of the levels of β-GLOBIN chains that 
transports hemoglobin in erythrocytes, due to mutations in one or more GLOBIN genes. A 
translocation in these genes removes cis-regulatory sequences, affecting their expression and 
consequently a disequilibrium in the expression of β-GLOBIN genes (Pennacchio et 
al.,2013).       
Mutations in TFBSs within enhancers can result in misregulation of target genes 
having as consequence the loss of a normal cell type or tissue (Lee & Young, 2013). The 
recent advances in the study of transcriptional cis-regulation have led to a better 
understanding of dysregulation of gene expression in several human diseases (Lee & Young, 
2013). One example of genetic variations are single nucleotide polymorphisms (SNPs), that 
have been identified in several whole-genome sequencing projects and computational 
analysis (Altshuler et al., 2012; Peters et al., 2012; Yngvadottir et al., 2009). These kind of 
variations are mostly located in non-coding regions and some can be specifically associated 
to human traits and complex diseases (Fig 6) (Lee & Young, 2014; Ernst, 2011; Hindorff et 
al., 2009; Maurano et al., 2012; Zhang & Lupski, 2015). 
 
 
 
Figure 6 – A. Normal situation – The chromatin loop is formed and the distally TF bind to enhancer in order to activate the 
transcription, sideways with Pol II; B. Disease associated SNPs – The chromatin loop is impaired, the TF binding site 
disrupted, and the transcription is affected. Adapted from Heuvel et al., 2015     
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The association between SNPs and diseases or traits is possible by performing 
genome-wide-association studies (GWAS). This type of studies access thousands of SNPs 
in a large sample of individuals to establish an association reliable between common genetic 
variants with diseases and traits (Schaid et al., 2018). Therefore, GWAS provide statistical 
evidences that the presence of certain SNPs in non-coding DNA can increase disease 
susceptibility (Hindorff et al., 2009; Li et al., 2014; Pennacchio et al., 2013; Zhang & Lupski, 
2015).  
 A combined analysis of GWAS and marks for enhancer prediction, such as DNase 
hypersensitivity, chromatin epigenetic marks, FAIRE and ChIP, many of them explored in 
large consortiums as the ENCODE project, allowed to infer that SNPs associated to disease 
may be often located in predicted enhancers. (Ahonen et al., 2009; Degner et al., 2012; 
Trynka et al., 2013). Maurano and coworkers observed that within 5134 SNPs associated 
with 654 phenotypes, 77% overlap with DNase hypersensitivity region (Maurano et al., 
2012). In addition, Hindorff and co-workers and Li and colleagues have detected that 88% 
of disease associated variants are located in non-coding regions (Hindorff et al., 2009; Li et 
al., 2012).   
 One example of a disease associated SNP is preaxial polydactyly, as referred before. 
It is described that this disease is caused by mutations in one distal enhancer, ZRS, of the 
target gene SHH.  (Lettice et al., 2002; Lettice et al., 2003). The analysis of the putative 
TFBS conserved in ZRS sequence showed consensus binding sites for homeobox protein 
CDX-1 (CDX), meis homeobox 1 (MEIS1) and SOX9, which are TFBS involved in limb 
development (van den Akker et al., 2002).Three of the six mutations showed to be the cause 
of  disruption of  CDX binding site, contributing to the disease (Evans, 2007; Lettice et al., 
2003).  
 Another example is Hirschsprung disease, where the RET gene is affected, by the 
presence of three SNPs in MCS enhancer, in intron 1. Interestingly, one of the three 
mutations in RET reduces their expression directly by affecting  SRY box 10 (SOX10) 
binding, being the other two mutations an indirect contribution  (Emison et al., 2005; Fisher 
et al., 2006; Grice et al., 2005; Sribudiani et al., 2011).  
Apart from the evidences from GWAS in the association of genetic variants to 
diseases, it is necessary to validate the putative functional impact of these variants on 
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biological processes, the inherent molecular function and the pathways that can connect the 
variants to the disease (Li et al., 2014). To reach this aim, it is imperative the development 
of suitable assays including the use of in vivo models (Pennacchio et al., 2013; Zhang & 
Lupski, 2015).  
3.1.Type 2 diabetes and cis-regulation 
 
Type 2 diabetes (T2D) is a complex disease and one of the most common complex 
traits worldwide, affecting more than 300 million people.  T2D is characterized mostly by 
the dysfunction of the endocrine pancreas (Fig 6), leading to insulin deficiency and loss of 
glucose homeostasis. However, the underlying molecular mechanisms are poorly understood 
(Alejandro et al., 2014; Pasquali et al., 2014; Sara, 2009; Chatterjee et al., 2017).  
T2D has been associated to obesity, cardiovascular risk and hyperglycemia, caused 
by genetic susceptibility and environmental factors (Saxena et al., 2007). The environmental 
factors englobe lack of exercise, diet and aging. The aging factor is related to the β-cells 
decrease in proliferation capacity (Avrahami & Kaestner, 2012; Bhushan et al., 2013; Teta 
et al., 2005). The genetic mutations related to insulin insufficiency are rare and single genetic 
alterations does not seem to be the main cause of T2D, however, a considerable number of 
affected genes might contribute to the disease.   
 
 
 
 
 
 
 
    
 
Figure 7 – Islet of Langerhans – endocrine cells. The endocrine pancreas dysfunction leads to T2D.    
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One of the most recent hypotheses is that the presence of SNPs in non-coding cis-
regulatory sequences, such as enhancers of genes required for proper β-cell function can 
cause susceptibility to the disease. Supporting this hypothesis, several variants associated to 
T2D have been identified in non-coding cis-regulatory sequences in the past recent years 
(Morris et al.,2012).  
3.1.1. Type 2 diabetes associated SNPs by genome wide association 
studies 
Currently, several studies have shown that SNPs associated to a large number of 
diseases are enriched in non-coding cis-regulatory enhancers (Dunham et al., 2012; Hindorff 
et al., 2009; Maurano et al., 2012; Trynka et al., 2013). GWAS have been extremely 
important to identify and determine the frequency of these SNPs (Human Genome 
Sequencing Consortium ,2004), which can be analyzed by the presence of allelic variants in 
linkage disequilibrium (LD). It is assumed that two allelic variants are in LD when there is 
a non-random association of alleles at different genome locations (Mohlke and Scott, 2012).  
Nowadays, there are approximately 88 established and published loci associated to 
T2D and 83 for glycemic traits (Mohlke & Boehnke, 2015).   
Additionally, Pasquali and colleagues (Pasquali et al., 2014) have done a recent 
important contribution for the study of T2D genetics. In a large-scale study, the authors 
performed FAIRE-seq and ChIP-seq for epigenetic marks for enhancers activity (H3K4me1 
and H3K27ac) to identify pancreatic enhancers. In addition, the authors performed ChIP-seq 
for islet TFs to predict their corresponding TFBS. The result was the identification of 
genomic sequences with cis-regulatory enhancer function active in the endocrine pancreas 
and targeted by specific islet TFs. Interestingly, the authors showed that SNPs associated to 
T2D were enriched in these enhancers. Thus, the T2D associated variants might have the 
potential to disrupt TFBS and islet enhancer activity, potentially causing a dysregulation of 
target genes. This way it was possible to integrate all the maps of epigenetic marks and 
TFBSs and create a complete and detailed dataset regarding the transcriptional regulation in 
pancreatic islets (Fig.8) (Pasquali et al., 2014).    
As presented in the example above, there are genomic approaches that allow to 
predict active enhancers genome wide for a specific tissue like the endocrine pancreas. 
However, predictions should be validated by in vivo and in vitro assays. Combining the 
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development of better predictions and sensitive and accurate methods of validation of 
enhancer activity it will be possible to better understand how genetic variants might impact 
in islet enhancer activity and consequently in islet function, resulting in human T2D.    
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Figure 8 – TFBSs, active chromatin and histone modifications profile maps, showing the signals and the relation 
between the peaks. The islet specific TF showed ta pattern in binding in accessible chromatin sites. Adapted from 
Pasquali et al., 2014.  
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3.1.1.1.The case of rs163184 and rs13266634 T2D associated SNPs 
a) rs163184 
One of the many SNPs identified to be associated to T2D is the rs163184. This SNP 
is located in an intronic region of KCNQ1 (potassium voltage-gated channel subfamily Q 
member 1) gene. The wild-type (WT) allele allows the binding of SP3 TF, directly, and 
LSDK1/KDM1A (lysine-specific histone demethylase) molecule, indirectly, via formation 
with SP3 TF complexes, stimulating the transcriptional activity of the gene. These bindings 
affect CDKN1C gene expression, being overexpressed, as demonstrated by Hiramoto and 
colleagues (Hiramoto et al., 2018). 
CDKN1C is a negative regulator β-cells proliferation. Therefore, it can lead to a 
reduced insulin production, causing susceptibility to T2D (Hiramoto et al., 2018). 
b) rs13266634 
The SNP rs13266634 was identified as an established locus for T2D. This SNP is 
located in chromosome 8, in SLC30A8 gene (Mohlke & Boehnke, 2015) that encodes  for a 
zinc transporter, known to be required for zinc transport through the cell membranes and 
extracellular matrix (Faghih et al., 2014). The zinc flux is necessary to insulin secretion 
(Rutter, 2010; Xiang et al., 2008).  
Many studies with single nucleotide variants in this gene have been done, however, 
the results are contradictory.  
Flannick and colleagues demonstrated that 65% of the single nucleotide variants in 
SLC30A8 resulted in a truncated protein and a reduced T2D risk (Flannick et al., 2014).  
Other evidences supported the hypothesis that when the rs13266634 SNP is not 
present, the expression of SLC30A8 increases the susceptibility to T2D (Mohlke & Boehnke, 
2015; Xu et al., 2011). It has also been described that rs13266634 presence reduces the 
activity of the zinc transporter (Nicolson et al., 2009; Xiang et al., 2008). Other authors also 
demonstrated that the risk allele associated variant was associated to a lower insulin secretion 
and response (Horikoshi et al., 2007; Kirchhoff et al., 2008).     
 Studies in Slc30a8 knockout mice also showed intriguing results. The phenotype 
was variable depending the gender and genetic background, suggesting that a perturbed zinc 
transporter will result in different biological responses (Flannick et al., 2014).  
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Further studies should be done to clarify the impact and the mechanism behind 
associated to this particular variant.  
4. Models to test pancreatic enhancers 
Putative enhancers can be validated by in vivo (Dorschner et al., 2004) or in vitro 
(Heintzman et al., 2007) reporter assays.     
4.1.  In vitro - cell lines 
Cell lines are an animal-free tool that allow to study several physiological processes 
and pathologies. It is also possible to manipulate cell lines, by transfection, introducing 
reporter constructs, which contain reporter genes like luciferase, to test enhancer activity 
(Skelin et al., 2010).  
However, cell lines can change their characteristics over time, showing 
chromosomal, genetic and protein expression abnormalities. (Skelin et al., 2010).   
The main challenge of β-cell lines creation relies in the difficulty to mimic the same 
characteristics of the parental tissue, the insulin secretion and cell-to-cell interaction. One 
good example of a β-cell line is MIN-6, a transgenic mouse insulinoma cell line. It derives 
from transgenic C57BL/6 mice insulinomas that express an insulin-promoter/T-antigen 
construct, forming islet-like cells (Ishihara et al., 1993).  
Many attempts were made to create a stable human β-cell line, however, the human 
lines created were not capable to secrete insulin, grow and were not stable in their function. 
Recently, it was established a promisor human β-cell line, from targeted oncogenesis in fetal 
pancreatic tissue that reproduces, in part, all the characteristics inherent of normal β-cells 
(Andersson et al., 2015; Ravassard et al., 2011; Scharfmann & Pechberty, 2014; Weir & 
Bonner-weir, 2011). 
Enhancers have a tissue specific activity, however, cell lines are not a good system 
to demonstrate this tissue specificity, in contrast to in vivo models. Thus, the in vitro 
enhancer assays may not represent accurately the molecular and physiological cell 
mechanisms that might be active in vivo.  
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4.2. In vivo - Zebrafish 
Zebrafish (Danio rerio) is a freshwater and a small bony fish. This species occupies 
shallow and highly vegetated regions and being omnivores, they feed on small insects, 
zooplankton and phytoplankton (Engeszer et al., 2007). Currently, the zebrafish is one of the 
most used model organisms in biomedicine and developmental biology, since genetic and 
embryological methods can be easily applied. It is cheap and easy to maintain in the 
laboratory, reproduces widely all year and it is possible to collect hundreds of eggs in one 
week. Furthermore, zebrafish reach the sexual maturity at 2-3 months, being appropriate for 
selection experiments and the creation of stable transgenic lines. Besides these advantages, 
the zebrafish embryos are transparent, which allow to follow the embryo development 
through time (Fig 9 - (Kimmel et al., 1995)  (Grunwald & Eisen, 2002 ; Amsterdam & 
Hopkins, 2006) .  
In the zebrafish genome, it has been described more than 20,000 genes and 69% of 
the these genes have orthologues in human (Howe et al., 2013; Tiso et al., 2009) .  Besides 
the public availability of the zebrafish genome sequence, there are many other tools that are 
also available such as transgenic and mutant lines (https://zfin.org/) ( Howe et al., 2013).  
All these characteristics makes the zebrafish a perfect model organism to study 
several diseases in laboratory (Engeszer et al., 2007; Seth et al., 2013).    
4.2.1. Zebrafish pancreas development  
The zebrafish pancreas has two important compartments: an exocrine and an 
endocrine compartment (Tiso et al., 2009). The exocrine compartment comprises the acinar 
cells that produce digestive enzymes and the endocrine compartment corresponds to the 
islets of Langerhans, where the hormones are secreted to the plasma, regulating the blood 
glucose levels (Prince et al., 2017).  
Figure 9 –Zebrafish developmental stages in segmentation period (10-24h). The embryos are transparent, being 
possible follow all the developmental stages. Based on Kimmel et al., 1995.   
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The formation of the zebrafish endocrine islet begins at 24hpf (Hours post-
fertilization) and it is positioned dorsally to the yolk (Fig 10). At 48hpf, the zebrafish larvae 
have already an endocrine islet  composed by insulin and somatostatin cells, bounded  to 
glucagon and PP cells (Biemar et al., 2001; Huang et al., 2001; Tiso et al., 2009) (Fig.10). 
 
 
 
 
 
 
Before β-cells differentiation, there is expression of mRNA from four crucial 
transcription factors, Pax6, Nkx6.1, NK6 homebox 2 protein (Nkx6.2), and pancreas 
associated transcription factor 1A (Ptf1A), being considered the cell progenitors of the 
pancreas, giving rise to all differentiated endocrine cells (Prince et al., 2017). The specific 
endocrine precursors are Isl-1, Neurod1 and achaete-scute family bHLH transcription factor 
Figure 10 – A. It was constructed an plasmid vector containing an insulin promoter and Tol2 elements being possible the 
GFP expression in β-cells, when integrated in the genome; B. GFP expression in β-cells in 3 day old embryo; C. Confocal 
image (bright field) showing GFP expression in β-cells in 10 day old larvae; C and D. Zoomed confocal image of the 
endocrine islet at 10 year old showing the endocrine islet domain, regarding β-cells (Huang et al., 2001).        
Figure 11 – Zebrafish endocrine pancreas principal development lineages. Adapted from Prince et al., 2017 
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1b (Ascl1b), being responsible for differentiation of endocrine pancreatic islets (Biemar et 
al., 2001; Delporte et al., 2008; Parsons et al., 2009).  
Pdx1 and Nkx6.1 have a crucial function in pancreas development and β-cells 
maturation, being expressed in differentiated β-cells ( Kimmel et al., 2015). Recently, it has 
been described that Pdx1 is important for glucose metabolism (Jörgens et al., 2015) and 
activation of INSULIN expression in specific reporter assays (Menting et al., 2014).  
The understanding of molecular pathways and the morphological changes in 
endocrine islet in zebrafish is possible due to the discover of specific biomarkers (Schiavone 
et al., 2014) allowing the development of reporter genes constructs and the creation of 
transgenic reporter lines, which allows the in vivo visualization of the pancreas. One example 
is the Tg(sst:mCherry) line, which labels in vivo the somatostatin (sst) cells, allowing the in 
vivo visualization of the endocrine islet (Fig.12).  
 
 
4.3. Zebrafish as a model to study type 2 diabetes non-coding variants 
The zebrafish pancreas presents several similarities with human pancreas. The 
resemblances in function and structure allow the possibility to study the molecular 
mechanisms and the phenotypes associated to T2D (Kinkel and Prince, 2009).   
T2D, is one of the most prevalent and challenging diseases in which genetics remains 
to be understood (Lu et al., 2018). Zebrafish has emerged as a potential tool to study  T2D 
associated variants through different approaches, such as transgenesis assays. 
   
 
 
 
Figure 12 – mCherry protein expression in δ- 
cells in endocrine pancreas of a 48hpf old 
embryo (Tg(sst:mCherry) reporter line). Leica 
M80. 
δ-cells 
sst-mCherry 
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4.3.1. Transgenesis assays 
In zebrafish transgenesis assays to test enhancers, the sequence of interest to be tested 
is cloned in a vector, usually a transposable element to facilitate transgenesis, containing a 
reporter gene. The reporter gene usually encodes a fluorescent protein whose expression can 
be visualized in vivo. The vector is constructed in order to locate the sequence to be tested 
upstream of a minimal promoter and the reporter gene, which will allow the expression of 
the reporter gene when the cloned sequence acts as an enhancer (Narlikar & Ovcharenko, 
2009).  The vector is microinjected in one-cell stage zebrafish embryos and integrated 
randomly in to the genome. The expression pattern generated by the in vivo reporter gene 
allows the characterization of the tissue specific activity of the tested enhancer (Bessa et al., 
2009; Soboleski et al., 2005; Kawakami, 2007) (Fig 13). 
Transposons are mobile DNA sequences flanked by terminal repeats and an encoded 
enzyme, transposase, that when recognize specific DNA sequences in the genome, can 
activate the capacity of replication in the same genome (Plasterk, 1993). Tol2 is a transposon, 
being the most used system to create transgenic zebrafish lines, once has a high percentage 
of integration and transmission through generations (Kawakami et al., 2004).   
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Figure 13 – Transgenesis in zebrafish. The transposase mRNA and a DNA plasmid containing Tol2, a promoter and a 
reporter gene (GFP – green fluorescent protein) are co-injected in one-cell stage egg. The construct is excised from 
de plasmid, allowing the integration in the zebrafish genome.  This insertion is transmitted to the next generation (F1), 
when the original injected generation is crossed with WT (wild-type) fish.  In this specific case, the promoter/enhancer 
is specific for spinal cord. Adapted from Kawakami, 2007. Images from http://www.zf-
health.org/information/factsheet.html and http://dgallery.s3.amazonaws.com/zebrafish.png.   
 
  
Co-injection in one-cell stage egg 
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5. Hypothesis and main objectives 
The emerging of large-scale studies and the total sequencing of human genome has 
provided important biological tools to identify cis- regulatory regions and to predict putative 
enhancers that might be fundamental for a good function of specific genes associated to 
several diseases. SNPs located in these regulatory regions can cause susceptibility to that 
kind of diseases, such as T2D. However, the study of putative enhancers is poorly known, 
due to the lack of investigations and validations in vivo. 
The working hypothesis of this study is that T2D associated SNPs might impair 
TFBS important for endocrine enhancer activity in endocrine islets, contributing for disease 
susceptibility.  
 The aims are:  
a) Identify human putative enhancers that overlap with described SNPs associated 
to T2D;  
b) Test the enhancer potential of the identified sequences using in vivo reporter 
assays in zebrafish; 
c) Analyze the impact of the presence of SNPs in the enhancer activity, for 
sequences validated as enhancers.  
Overall, this work will allow us to better understand the impact of non-coding 
variants in endocrine enhancers, which can help to understand the molecular and genetic 
mechanism behind the development of T2D. 
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II. Materials and methods 
1. SNPs and putative enhancers selection 
The putative enhancers were selected based on Mohlke & Boehnke (2015) and 
Pasquali et al. (2014) GWAS bioinformatics data. The 176 sequences overlapping with T2D 
associated SNPs (Mohlke & Boehnke, 2015) were analyzed in UCSC Genome Browser 
(GRCh36/hg18) (https://genome.ucsc.edu/), using Pasquali and colleagues data and 
ENCODE data (Rosenbloom et al., 2012; Pasquali et al., 2014) for the presence of epigenetic 
marks in histones (H3K4me1 and H3K27ac). ENCODE data was used for different cell 
lines: Gm12878, a lymphoblastoid cell line, H1ES, a human embryonic stem cell line, 
HMEC, human mammary epithelial cells, HSMM, human skeletal muscle cells and 
myoblasts, HUVEC, a human umbilical vein endothelial cell culture, K562, lymphoblasts 
from bone marrow, NHEK, normal human epidermal keratinocytes and NHLF, human lung 
fibroblasts (Rosenbloom et al., 2012). The analysis was refined using data obtained from 
human pancreatic islets (Pasquali et al., 2014). The islet samples were analyzed by FAIRE 
and ChIP using the following marks: H3K4me1, H3K4m3, H3K27ac, CTCF (CCCTC-
binding factor), H2A.Z (Histone H2A.Z), PDX1, MAFB, NKX6.1, FOXA2 and NKX2.2 
(Pasquali et al., 2014).  
Additionally , the selected sequences were also explored in Islet Regulome Browser, 
(http://www.isletregulome.org/isletregulome/) (Mularoni et al, 2017).  
The analysis of these data resulted in a list of ten putative enhancers and overlapping 
SNPs associated to T2D (Table 2).      
2. Primers design and PCR amplification 
The PCR reactions were performed using the proofreading i-MAX II Taq DNA 
Polymerase (iNtRON Biotechnology, Inc) in a final volume of 20µL, containing 2µL of 10X 
PCR Buffer, 0,75 µL of Forward and Reverse Primers (10 µM), 2µL of dNTP mix 
(10mM/each NTP), 13µL of nuclease-free water and 0.5 µL of i-MAX II DNA Taq 
polymerase. Amplifications were performed at 94ºC for 3 minutes, followed by 35 cycles at 
94ºC for 30 secs, 63-65ºC (depending on the melting temperature; Table 3) for 40 seconds, 
72ºC for 1 minute/kb (depending of the size of the amplicon; Table 3) and a final extension 
at 72ºC for 10 minutes.  
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The PCR amplification was confirmed by analyzing the PCR product in 1% agarose 
gels stained with SYBR Safe (NZYtech). The ladder used was Gene Ruler 1kb (Thermo 
Scientific). The amplified product bands were excised from the agarose gel and purified 
using NZYGelpure kit (Nzytech), according to the standard protocol.  
3. pCR8/GW/TOPO vector cloning and chemically competent bacteria 
transformation 
The PCR products were TA cloned into pCR8/GW/TOPO (Invitrogen – Thermo 
Fisher Scientific). The vector is Gateway-adapted to provide an easy recombination of the 
PCR product of interest into any Gateway destination vector (Fig. 14).   
The cloning reaction consisted in a mix of purified PCR product (3 µL), salt solution, 
the commercial solution from the kit (1 µL), pCR8/GW/TOPO vector,  diluted to 1/5 in 
dilution buffer (50& glycerol, 50mM Tris-HCl (ph=7.4), 1mM EDTA, 1mM DTT, 0,1% 
Triton X-100, 100 µg/ml bovine serum albumin (BSA) in ddH2O) (1 µL), to a final volume 
of 6 µL, followed by a 30 minute of incubation at room temperature.  
After incubation, 3 µL of each reaction were added into to 50 µL chemically 
competent bacteria and incubated in ice for 30 min. Cells were heat-shocked for 30 seconds 
at 42ºC and immediately transferred into ice for 2 min. 700 µL of Lysogeny broth (LB) were 
added the cells and incubated at 37ºC, for 1 hour with shaking. Cells were plated in LB agar 
plates containing 100 μg/mL spectinomycin and incubated overnight at 37ºC. The 
Figure 14 – The sequence of interest was amplified by PCR, using a set of specific primers. The amplified sequence was 
cloned into the commercial vector pCR8/GW/TOPO. The attL1 and attL2 flanks where the sequence is inserted, by TA 
cloning. The EcoRI enzyme restriction site is represented in the vector. 
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pCR8/GW/TOPO vector has spectinomycin resistance (Fig.14) to an efficient selection of 
the colonies. 
Isolated colonies were picked from the plate and were transferred to LB containing 
spectinomycin and incubated overnight at 37ºC. Plasmid DNA was extracted using 
NZYMiniprep (Nzytech), according to the standard kit protocol.  Plasmids DNA were 
digested with EcoRI enzyme (Anza; 8000 units) to confirm the insertion of the sequence of 
interest. This reaction consisted in 3 µL of miniprep product, 0,3 µL of the restriction enzyme 
to a final volume of 20 µL, followed by 2 hours of incubation at 37ºC. The digestion product 
was analyzed by 1% agarose gel electrophoresis and plasmids containing the PCR amplified 
sequence were sequenced for confirmation. 
4. Z48 based vector recombination  
The PCR product sequence contained in the pCR8/GW/TOPO was recombined into 
a destination vector, the Z48 vector (Fig 15). This vector has a minimal promoter upstream 
of the GFP (green fluorescent protein) reporter gene and a Z48 enhancer, that drives 
expression in the midbrain (Cebola et al, 2015). The vector contains a Tol2 transposon and 
ampicillin resistance.  
 
 
 
 
 
 
 
 
 
 
The recombination reaction was performed using a Gateway™ LR Clonase™ II 
Enzyme (Invitrogen - Thermo fisher scientific) in a final volume of 2,5µl, containing 1 µl of 
Figure 15 – The DNA fragment, after TOPO vector cloning, the entry vector, is recombined to a Z48 based vector, the 
destination vector, to test the enhancer activity of the sequence.  
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pCR8/GW/TOPO plasmid with the cloned sequence, 1 µl of Z48 destination vector, both at 
50 ng/ µl and 0,5 µl of clonase enzyme. The reaction was incubated overnight, at 25ºC. To 
end the reaction, 0,25 µl of Proteinase K (Thermo fisher scientific) was added and incubate 
at 37ºC, for 10 min. The transformation was performed using chemically competent cells. 
Transformed bacteria were selected with ampicillin and isolated colonies were picked and 
grown to extract plasmid DNA.  
5. Phenol/Chloroform DNA purification 
Z48-plasmids were purified by a phenol/chloroform purification protocol: 
phenol/chloroform with isoamyl alcohol was added to the sample diluted in RNAse free 
water treated with DEPC (70 µl to a final volume of 100 µl), followed by vortex and 
centrifugation (13000 rpm), for phase separation (the DNA stayed in the aqueous upper 
phase).The aqueous phase was transferred to a RNAse free eppendorf and 100 µl of 
chlorophorm was added, vortexed and centrifuged as mentioned before. The aqueous phase 
was collected; 10 µl of sodium acetate (AcNa 3M) was added 100 µl of aqueous phase and 
200 µl of ethanol (100%) to precipitate the sample, during 1h at -20ºC. Next, the sample was 
centrifuged 15 min (13000 rpm) at 4ºC and ethanol was removed. The pellet was diluted in 
15 µl of DEPC treated water and quantified in a nanodrop (NanoDrop ND-1000 
Spectophometer -Thermo Scientific).  
6. Zebrafish maintenance and microinjection  
6.1. Zebrafish husbandry 
Zebrafish embryos were maintained according to standard protocols (Westerfield, 
2000) at 28ºC in E3 medium (NaCl, KCl, CaCl.2H2O and MgCl.6H2O). Zebrafish adults 
were maintained in a 14/10h photoperiod (light/dark), water temperature was kept at 26/27ºC 
and adults were fed three times a day. 
6.2. Microinjection  
6.2.1. Tol2 transposase mRNA synthesis 
A Tol2 cDNA (complementary DNA) containing plasmid (Chien lab, 2007) was 
transformed using chemically competent cells and plated in LB agar plates with ampicillin 
(100ng/ µl). Three isolated colonies were transferred to LB broth with ampicillin and 
incubated overnight at 37ºC. Plasmid DNA of each colony was extracted and digested with 
NotI (Anza), to linearize the vector. The digestion reaction consisted in 1µl of enzyme, 4,5µl 
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of DNA plasmid, 2 µl of buffer 10x and 12,5 µl of high pure water. NotI enzyme was used 
to linearize Tol2 cDNA vector, to transcribe the product, before purification by 
phenol/chloroform. The digestion product was analyzed by 1% agarose gel electrophoresis, 
extracted and purified by phenol/chloroform.   
Tol2 RNA was transcribed in vitro using a mix reaction with 10 µl of transcription 
buffer 5x, 5 µl of DTT - dithiothreitol (50mM) and 5 µl of NTP mix (10mM A, 10mM U, 
10mM C and 5mM G), followed by a 5 min incubation at 37ºC, then 5 µl of 5`CAP (25mM) 
were added. After 1 min of incubation, 12 µl of phenol/chloroform purified DNA was added, 
followed by an incubation of 1min. NZY Ribonuclease inhibitor was added in the reaction 
(2 µl), with 1min of incubation, then 1 µl of RNA polymerase (SP6), followed by 1h of 
incubation. This last step was repeated. All the incubations were made at 37ºC.         
6.2.2. Sephadex and phenol/chlorophorm purification  
 RNA was purified using an adapted sephadex protocol. The piston of 1ml sterilized 
syringe was removed, in order to insert sterilized and DEPC treated aquarium filter 0,1mm. 
Next, sepahdex (Sigma-Aldrich) solution (1ml) (diluted in Tris- EDTA) was added to the 
top. Then, the syringe was placed in a 15ml falcon to discard liquid and centrifuged (4000 
rpm) for 5 minutes, at 4ºC. The flow-through was discarded. To an efficient purification, the 
sephadex column, after the first centrifugation, has to reach at 0,6mm. Next, 50 µl of high 
pure water were added to column with an 0,5 eppendorf attached in the syringe, and the 
column was centrifuged again (4000 rpm) in the same conditions. It was checked if the 
volume in the 0,5 eppendorf was 50 µl. If so, the synthetized RNA was loaded in the column 
and was placed a new 0,5 eppendorf in the syringe. It was followed a new centrifugation 
(4000 rpm), with the same conditions. The RNA was collected to a new RNAse free 
eppendorf and placed in ice. To certify the total collection of the RNA, another 50 µl of high 
pure water was added in the column and centrifuged (4000 rpm). The water was added to 
the RNA and placed in ice. Next, phenol/chloroform purification was performed, the RNA 
quantified and stored at -80ºC.   
6.2.3. Zebrafish breeding and embryos collection 
One male and two females were placed in a breeding tank overnight separated by a  
divider. In the next morning, when the lights turned on, the divider was removed, and the 
fish started to reproduce. The breeding tanks have a net at the bottom, so the eggs can fall 
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through the net and not be eaten by the adult fishes. Eggs were collected to proceed to 
microinjection. An in vivo reporter line of the endocrine pancreas was used, Tg (sst: 
mCherry). This reporter line has a sst promoter that drives expression of mCherry in δ-cells.  
6.2.4. Microinjection at one-cell stage embryos   
Microinjections were performed using a Narishige microinjector. One cell-stage 
embryos were injected with 2-5 nanoliters containing transposase mRNA, at 25ng/ µl, the 
Z48 enhancer assay vector (25 ng/ µl) and 0,05% phenol red. After microinjection, embryos 
were maintained in E3 (embryo medium) medium with 0,2mM 1-phenyl-2-thiourea (PTU 
1x), to avoid pigmentation development. 
7. Fixation and DAPI staining 
At 48 hours for fertilization (hpf), microinjected embryos were selected by 
expression of GFP in the midbrain, dechorionated and fixed overnight in formaldehyde (4%, 
in PBS – phosphate-buffered saline – 1x). Then, embryos were washed with 500 µl of PBS-
T (0,1% Triton in PBS-1x) 5 min, at room temperature, followed by permeabilization, with 
500 µl of PBS-T 0,5%, during 30 min. After permeabilization, embryos were washed for the 
second time with PBS-T 0,1% and incubated with DAPI (1: 1000) in 200 µl of PBS-T 0,1%., 
for 4 hours at room temperature. After the incubation, embryos were washed 6 times (10 min 
each and the sixth, 30 min), with PBS-T 0,1%, at room temperature. PBS-T 0,1% was 
removed and 50% of glycerol in PBS 1x (NaCl, KCl, Na2HPO4 and KH2PO4 in ddH2O) was 
added. Microscopy slides were prepared using 50% of glycerol in PBS 1x. Embryos were 
analyzed in a confocal microscope (Leica - SP5II).     
8. Immunohistochemistry  
Embryos were fixed at 48 hpf, in formaldehyde (4%, in PBS – 1x) as previously 
described. Embryos were washed with 500 µl of PBS-T (0,1% Triton in PBS-1x) 5 min, two 
times. Permeabilization was performed with 500 µl of PBS-T 1%, for 2 hours, followed by 
a wash of 5 min with PBS-T 0,1%. Block with 200 µl of bovine serum albumin BSA in PBS-
T (5%), for 1 hour. Embryos were incubated with an anti-Nkx6.1(F55A10; Hybridoma bank) 
primary antibody (1:50) in 200 µl of BSA+PBS-T (5%), for 48 hours, followed by 6 washes 
with PBS-T 0,1% (5 washes, 10 min each and 1 wash for 30 minutes). The embryos were 
incubated with DAPI (1: 1000) and an anti-mouse secondary antibody (Alexa fluor 647 nm 
– 1:800) in PBS-T at 4ºC, overnight. After overnight incubation, embryos were washed, as 
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previously described and glycerol, at 50% in PBS 1x, was added. Microscopy slides were 
prepared using mounting medium (50% of glycerol in PBS 1x). Embryos were analyzed in 
confocal microscope (Leica - SP5II).     
 
9. Predicting the impact of T2D risk variants in TFBS - JASPAR analysis  
To predict how T2D risk variants could impact in the ability of TFs to bind to the 
respective sequences, JASPAR software was used. JASPAR uses a set of annotated position 
weight matrices for TFBS (Khan et al., 2018).   
The WT and risk variant sequences were analyzed using the 719 specific position 
weight matrices for vertebrates, available in JASPAR. Sequences were analyzed and ranked 
by position-specific score matrix (Tables 5, 6 and Supplementary data). The relative score 
is a threshold score between 0 and 1 and is calculated by (score - min_score) / (max_score - 
min_score), being more accurate than the total score (http://jaspar.genereg.net/) (Sandelin, 
2004).   
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III. Results and discussion 
1. Selection of putative enhancers that overlap with SNPs associated to T2D 
To identify putative enhancers that overlap with T2D associated SNPs we have 
combined datasets of ChIP - seq for epigenetic marks of enhancer activity, from different 
cell lines (H3K4me1 and H3K27ac; ENCODE PROJECT) (Rosenbloom et al., 2012) with 
a dataset of 176 described T2D associated SNPs (Mohlke & Boehnke, 2015). Once cell lines 
from different tissues (see materials and methods) might not be the best biological samples 
for the prediction of endocrine enhancers, we improved this analysis, using a ChIP-seq 
dataset from human endocrine islets (Pasquali et al., 2014). This dataset consisted in 
prediction of active endocrine enhancers by the presence of epigenetic marks for enhancer 
activity (H3K4me1, H3K4m3, H3K27ac, CTCF, H2A.Z). Additionally, an islet TFBS 
(PDX1, MAFB, NKX6.1, FOXA2 and NKX2.2) were identified by ChIP-seq. (Pasquali 
et al., 2014). The islet dataset can be consulted in Islet regulome browser 
(http://www.isletregulome.org/isletregulome/)  (Mularoni et al., 2017).  
 Ten sequences were selected by the consistent overlap of signal from the different 
mentioned datasets (Table 2).  
     Table 2 – Sequences selection, localization, TF associated and nearby genes. (Data from ENCODE UCSC Genome 
Browser and Islet Regulome Browser) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequemce SNP Coordinates (GRCh36/hg18) TF binding sites Nearby genes 
Seq790 rs7903146  C > T chr10:114,747,755-114,749,047 NKX2.2, FOXA2, NKX6.1, 
MAFB 
TCF7L2 
Seq219 rs2191349  G > T chr7:15,030,232-15,031,383 NKX2.2, MAFB, PDX1, 
NKX6.1 
DGKB 
Seq117 rs11708067  G > A chr3:124,547,836-124,549,066 NKX2.2, MAFB ADCY5 
Seq68 rs6813195  G > C chr4:153,739,117-153,740,469 PDX1, NKX2.2, FOXA2, 
NKX6.1, MAFB 
TMEM154 
Seq119 rs11920090  A > T chr3:172,199,576-172,201,167 FOXA2 SLC2A2 
Seq132 rs13266634  C > T chr8:118,251,516-118,256,576 NKX2.2, FOXA2 SLC30A8 
Seq58 rs58692659  C > A  chr6:37,883,211-37,884,278 PDX1, NKX2.2, FOXA2, 
NKX6.1 
ZFAND3 
Seq72 rs72695654  G > T  chr4:185,953,124-185,953,774 PDX1, NKX2.2, FOXA2, 
NKX6.1 
ACSL1 
Seq73 rs735949  T > C chr4:185,952,953-185,953,787 PDX1, NKX2.2, FOXA2, 
NKX6.1 
ACSL1 
Seq460 rs4607517  G > A chr7:44,201,930-44,202,603 NKX2.2 YKT6; GCK 
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Figure 16 (A-J) – Genomic landscape of the selected sequences. The relative size of the sequence in the genome is 
represented in grey. The TFBS determined by ChIP-seq of human islets are represented in the respective colors (PDX1 
– dark blue, MAFB – dark green, NKX6.1 – blue, FOXA2 – light green, NKX2.2 – light blue). The peak of acetylation 
determined in ChIP-seq is represented in black. Above, the profiles of acetylation and methylation in different cell lines 
from ENCODE data. In blue the nearby genes of the putative enhancer. In purple the SNP associated to T2D.       
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 For sequences seq117, seq68, seq119 and seq58 (Fig.16 – A, B, C and D), high levels 
of H3K4me1 were detected overlapping the T2D associated SNP or nearby regions. Also, 
for sequences seq73, seq72 and seq119, high levels of H3K27ac mark were detected (Fig.16 
– E, F and C). These results made us hypothesize that seq117, seq68, seq73, seq72 and seq58 
could be enhancers, although it is not known if seq117, seq58 and seq68 could be active or 
primed. Seq119 could be more robustly predicted as an enhancer since this sequence overlap 
broadly with H3K27ac and H3K4me1. To improve this prediction of putative pancreas 
enhancers, apart from ENCODE data, we have analyzed data from Pasquali and co-workers 
(Pasquali et al, 2014). Using pancreatic islets, this data allowed to predict enhancers by 
combining different epigenetic marks, H3K27ac, H3K4me1, H3K4m3, CTCF and H2A.Z, 
labeled as “active enhancers” (Fig.16). All the sequences overlapped with this cluster of 
“active enhancers”, except seq117 and seq132. Besides predicting enhancers, Pasquali and 
co-workers have also used ChIP-seq to identify the binding site of islet TFs (FOXA2, 
MAFB, NKX6.1, NKX2.2 and PDX1) in human endocrine islets (Pasquali et al., 2014).  
Seq790 shows binding sites for MAFB and FOXA2 (Fig16- H). FOXA2 is expressed 
in multipotent pancreatic progenitor cells and posteriorly expressed in differentiated β-cells. 
The dual role of FOXA2 and MAFB suggests that seq790 could be a putative enhancer with 
an important function in endocrine islet differentiation and maturation, as seq132 and seq117 
(Fig.16 – G and A). Seq790 also overlap with TFs present in differentiated cells: NKX6.1 
and NKX2.2. NKX6.1 is important for β-cell differentiation and has as target gene INSULIN, 
being also critical in  β-cell function ( Ahlgren et al., 1996; Taylor et al., 2013).   
Seq219 (Fig.16- I) shows binding sites for NKX6.1, MAFB, PDX1 and NKX2.2. 
PDX1 is required for pancreas development, β-cell differentiation and maturation, having, 
like NKX6.1, INSULIN as target gene (Ahlgren et al., 1996). Therefore, seq219 is a strong 
candidate to endocrine enhancer.     
Seq117 (Fig.16- A) and seq132 (Fig.16- G), showed a coincident binding profile for 
MAFB and NKX2.2. MAFB is expressed in multipotent pancreatic progenitor cells of α and 
β-cells, being important for its inherent  differentiation (Qiu et al., 2017). In addition, MAFB 
is also required for β-cell maturation (Qiu et al., 2017), suggesting that seq117 could be a 
putative enhancer with an important function in endocrine islet differentiation β -cell 
maturation. NKX2.2 is a transcriptional activator of NEUROD1 expression, being also 
important for the maturation of β-cells (Gu et al., 2011; Mastracci et al., 2013).  
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Seq58, seq73 and seq72 (Fig.16-D ,E  and F ) show binding sites for all islet TFs, 
except MAFB, while seq68 (Fig.16 – B) show binding sites for all specific islet TFs: 
NKX6.1, NKX2.2, FOXA2, MAFB and PDX1.   
Seq460 (Fig16- J) only overlaps with NKX2.2 binding, while seq119 (Fig.16-E) did 
not show any binding site of the analyzed TFs. 
All these data together allowed to build a list of high confidence putative enhancers 
(Table 2). 
Although the target genes of these putative enhancers remain unknown, nearby genes 
might be good candidates, therefore, we have analyzed which genes are in closest vicinity 
to the respective putative enhancers (Table 2). For seq790 (Fig.16-H), the nearest gene is 
TCF7L2, a gene for which its loss-of-function has been described to affect INSULIN 
expression. In addition, its loss-of-function has been associated to T2D, since the presence 
of some genetic variants in the coding region of TCF7L2 affect the levels of the protein and 
show T2D related phenotypes  (Gloyn, et al.,2009). Seq219 (Fig.16-I) is in the genomic 
vicinity of DGKB. Interestingly, genetic variants in the coding region of this gene have been 
associated with a lower insulin release in the initial phase of the response to glucose from β-
cells (Billings & Florez, 2010). Seq117 (Fig.16-A) is located in an intron of the ADCY5 
gene. This gene encodes an enzyme that helps to convert adenosine triphosphate to cyclic 
adenosine monophosphate being involved in signaling processes and in β-insulin secretion  
(Roman et al., 2017). SNPs located in the coding region of this gene are associated to T2D 
(Roman et al., 2017). Seq68 (Fig.16- B) has TMEM154 as the most nearby gene, that encodes 
a transmembrane protein. Variants in the coding region of this gene might have an effect in 
secretion of intestinal hormones that can affect pancreatic β-cells (Harder et al., 2015), which 
could be indirectly associated to T2D. The SLC2A2 gene is located nearby seq119 (Fig.16-
C) and encodes a transmembrane carrier protein, also known by GLUT2 (glucose transporter 
2), that has been shown to be important for proper insulin secretion (Laukkanen et al., 2005). 
Seq132 (Fig.16-G) is located in a SLC30A8 intron that encodes for a zinc transporter, that is 
necessary for insulin crystallization and secretion (Rutter, 2010; Xiang et al., 2008). 
Surprisingly, studies with this gene have shown that 65% of the coding variants present in 
in SLC30A8 resulted in a truncated protein and a reduced T2D risk (Flannick et al., 2014).   
The ZFAND3 gene is the nearest gene of the seq58 (Fig.16-D), which encodes a zinc 
finger protein. It is suggested that the variants located in these gene have a sex specificity in 
American Indian population (Muller et al., 2017), since coding SNPs in ZFAND3 are 
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associated to T2D in woman (Muller et al., 2017). Sequences seq72 (Fig.16-F) and seq73 
(Fig.16-E) are both located in ACSL1 gene intronic regions. This gene encodes a long-chain 
acyl-CoA synthetase 1, that has the capacity to covert fatty acids into acyl-CoAs. The 
specific role of this gene in the pancreas domain it is not known in humans. However, the 
study of common variants in the coding region of ACSL1 by meta-analysis show an 
association with fasting glucose and diabetes (Manichaikul et al., 2016). Lastly, seq460 
(Fig.16-J) has two very nearby genes: GCK and YKT6.  GCK encodes glucokinase, necessary 
in glucose metabolisms pathways by β-cells, modulating insulin secretion. Mutations in 
GCK gene are, consequently, directly related to T2D, by altering this enzyme activity 
(Gloyn, 2003). YKT6 gene encodes a protein receptor and it is involved in vesicular transport 
between membranes. It has roles in exosomes production and release in lung cancer cells. 
Due to its role, SNPs in the coding region of this gene are related to cancer cells survival 
(Ruiz-Martinez et al., 2016), but how the variants can be related to glucose homeostasis is 
unknown (Choi et al., 2017),  
In summary, we have selected genomic sequences that overlap with SNPs associated 
to T2D and with epigenetic marks for enhancer activity. In addition, most of these sequences 
have binding sites for islet TFs and the nearby genes are associated to endocrine pancreas 
dysregulation. These characteristics make these sequences as good candidates to be 
enhancers, which activity might change in the presence of T2D associated variants. To 
determine if indeed these predictions are robust, sequences must be tested for enhancer 
activity.  
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2. PCR amplification of putative endocrine enhancers overlapping with T2D 
associated SNPs 
To amplify the selected putative enhancer sequences, we have designed primers 
flanking these genomic sequences (Table 3). Fragments sizes varied from 651 bp to 1687 bp 
(base-pairs). PCR amplification was performed using human genomic DNA as a template 
and a Taq DNA polymerase with proofreading activity, as described in materials and 
methods. Resulting PCR products were run in an 1% agarose gel, bands were confirmed to 
have the expected molecular weight and then were excised from the agarose gel and purified 
using a gel pure kit as described in material and method section. Purified PCR products are 
show in figure 17.  
 
 
 
 
 
 
 
 
 
 
 
Sequence Forward primer 5`- 3`(bp) Reverse primer 3`- 5`(bp) Tm 
(Cº) 
Product 
size (bp) 
Seq790 AGGTGTGGGGGTATATGGTATCC CACCAGGTCATGGAAACTTAGCC 65 1293 
Seq219 CTACTGACATCAGCCAATGAGTCTAATACC GTCCTCCAGGGCCTCTATATTCATGG 65 1152 
Seq117 CTTCCCGGATGTGGAGATTCAGCC GGAGGAGAAAGGAGGAAGCAACACC 65 1231 
Seq68 CCTGGAGATTGTCTTCTAAGCTGC GCAACTCAGATTGCATCTAGAGCC 65 1353 
Seq119 ATGGCACAAACAAACATCCCACTCATTCC ACTAATGGGCTGGTAGAAGAGGGCC 65 1592 
Seq132 GCATTTACTGCCTCAAGAGAAAGC GTGGCAACAACTTGGTGGGG 63 1687 
Seq58 CTCTGAGAAGGAAATTGAACGC AAAACCTCACATTAAAGCCATCCC 59 1068 
Seq72 TTCGCAAAACATCTCATCACC CAGGGTGAGAACTGAAGGC 63 651 
Seq73 TCACCTGTGCCTGGCTGGG GTGGGGTGGCCTGCAGGG 63 835 
Seq460 GCCTATCTTCAAATCTCTACTTCCC GATCAGGAAGACAGCGCTTGG 63 674 
Table 3 – Primers used in PCR amplification and characteristics for each sequence SNP associated. 
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3. Cloning of the PCR amplified genomic fragments in PCR8/ GW/ TOPO vector  
After purification of the PCR products, DNA fragments were cloned in the 
PCR8/GW/TOPO vector. PCR8/GW/TOPO vector is a commercial TA compatible vector 
that is diluted in a TOPO isomerase mixture, facilitating the ligation of the amplified 
sequences. After the cloning reaction, DNA was transformed in chemically competent 
bacteria and plated in LB agar plates containing spectinomycin. Several colonies were 
selected to grow overnight in liquid media with spectinomycin and then plasmid extraction 
was performed. After extraction, plasmid DNA was cut with EcoRI to confirm the successful 
cloning of the sequences. EcoRI flanks the PCR8/GW/TOPO cloning site (Fig.18 – A and 
B). The digestion product had the DNA band of 2799 bp containing the vector backbone and 
a second band with the sequence of interest correct size (Fig.18-B).  
 
 
 
 
 
 
 
Figure 17 – Gel resulted from electrophoresis containing the product of the sequences PCR amplification (Seq58 –
1068bp; Seq117 – 1231 bp; Seq790 – 1293 bp; Seq219 – 1152 bp; Seq132 – 1687 bp; Seq460 – 674 bp; Seq73 – 835 
bp; Seq68 – 1353 bp; Seq119 – 1592 bp; Seq72 – 651 bp) Ladder Gene Ruler 1kb.   
Ladder 
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Figure 18 – A- Graphic scheme of TOPO and the cloned sequence; B - Gel electrophoresis resulted from 
electrophoresis containing the product of EcoRI enzyme digestion. (Seq58; Seq117; Seq790; Seq219; Seq132; Seq460; 
Seq73; Seq68; Seq119 and Seq72). A -The digestion product will have a DNA band of 2799 bp containing the vector 
backbone and an extra DNA band of the size of the cloned fragment. Ladder Gene Ruler 1kb.   
 
A 
B 
Ladder 
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4. Recombination of sequences to test for enhancer activity into Z48 transposon 
The cloned sequences in PCR8/GW/TOPO were recombined in Z48 destination 
vector (Fig. 19 - B). The sequences were cloned between two EcoRI enzyme restriction sites 
(Fig.19 – A). In this specific vector, there is a third EcoRI restriction site. Therefore, the 
digestion with this enzyme allowed to confirm the successful insertion of the sequences by 
the visualization of three fragments in electrophoresis gel (Fig.19-B and C).  The digestion 
product had the DNA bands of 4279 bp and 1835 bp from the vector backbone and a third 
band with the sequence of interest correct size (Fig.19-B).  
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 19 – A – Graphic scheme of Z48 based vector and the cloned sequene; B - Gel resulted from electrophoresis 
containing the product of EcoRI enzyme digestion. (Seq68; Seq219; Seq73; Seq119; Seq72; Seq117; Seq460; Seq58; 
C - Seq132; Seq790. The digestion product will be 4279 bp, 1835 bp and the size of the fragment. Ladder Gene Ruler 
1kb.   
 
C 
Ladder 
Ladder 
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5. In vivo transgenesis assays for endocrine pancreas enhancer activity in 
zebrafish 
5.1. Defining the endocrine pancreas domain of zebrafish using in vivo reporter 
lines 
To visualize zebrafish endocrine domain, we have used an in vivo transgenic reporter 
line Tg(sst:mCherry) that shows expression of mCherry in δ-cells. This reporter line contains 
the promoter of Somatostatin gene (sst) upstream of the mCherry reporter gene. To verify 
the position of β-cells relative to δ-cells, we crossed the sst-mCherry line with an in vivo 
reporter line for Insulin, containing the promoter of Insulin upstream of the in vivo reporter 
gene GFP. Embryos were grown up to 48hpf, a developmental time when the endocrine cells 
of zebrafish pancreas are already differentiated, and we analyzed the embryos by confocal 
microscopy (Fig.20). In all cases observed, the expression of GFP remained inside the 
expression domain of mCherry (Fig.20), showing that the sst-mCherry reporter line can be 
used to localize the zebrafish endocrine pancreas domain in further transgenesis assays to 
detect endocrine enhancers. 
     
 
 
 
 
 
 
 
 
 
Figure 20 – Representative image showing the pancreas endocrine domain (dash line), regarding two reporter lines 
Tg:sst:mCherry and Tg:ins:GFP.  Leica confocal SP5II; Zoom 2,91; Magnification 40x.  
 
        ins-GFP                             sst-mCherry                               DAPI                                MERGED 
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5.2. Zebrafish transgenesis using the Z48 transposon: controls  
 
 
 
 
 
 
 To test if the selected sequences (Table 2), cloned in Z48, are endocrine pancreatic 
enhancers, each Z48 vector was injected in one-cell stage zebrafish embryos from the sst-
mCherry reporter line (Fig.21; red arrow). The Z48 transposable element contains a minimal 
promoter upstream of GFP and a downstream enhancer that activates expression of GFP in 
the midbrain, which can be used as a control for the transgenesis (Fig.21; green arrow). After 
microinjection of each Z48 transposable element, if the mobilization of the Z48 transposable 
element into the zebrafish genome was efficient, GFP expression is detected in the midbrain 
of 48hpf embryos (Fig.21). At 48hpf, pancreas endocrine cells are already differentiated 
(Fig.20), being this the adequate developmental time selected to perform the current assay.   
The negative control for the current enhancer activity assay corresponded to a 
microinjection of the Z48 vector lacking a cloned sequence upstream of the minimal 
promoter, being denominated as Z48 empty vector. Upon injection and selection of embryos 
that presented GFP expression in the midbrain, embryos were analyzed in the confocal 
microscope to determine if GFP expression was detected in the pancreatic domain defined 
by the expression of mCherry in the sst-mCherry transgenic background. In forty-three 
embryos, positive for GFP expression in the midbrain, none has shown expression of GFP 
in the endocrine pancreas domain (Fig.22 – A and Fig.23). This negative control allowed to 
access the noise associated to random integrations of the transposable element in the 
zebrafish genome, also named position effect (Chung et al.,1993), establishing a minimal 
threshold to be compared with the results obtained with the tested sequences. Because noise 
was not observed in the negative control, it was important to determine the sensibility of the 
assay, otherwise false negative sequences could be identified. For that we have selected a 
Figure 21 – Representative image of the GFP expression pattern when the Z48 vector is correctly injected and 
integrated in the zebrafish genome. Tg:sst:mCherry; Leica M205.  
 
          GFP   sst-mCherry                                                                           
48hpf 
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positive control for the experiment (Fig.22 – B and Fig.23), which was the microinjection of 
a vector containing GFP as reporter gene under the control of the insulin promoter, known 
to drive robust expression in endocrine pancreas. Five out of nine embryos injected with the 
positive control showed expression of GFP in pancreas endocrine cells (Fig. 22- B and 
Fig.23). This result allowed to understand the level of integration and activity that it would 
be possible to expect injecting strong and robust enhancer.  
 
 
 
 
 
  
 
 
Figure 22 – A – Representative confocal images showing the negative control with no GFP in endocrine pancreas. B 
– Representative image of a positive control showing GFP expression in endocrine pancreas domain.; The dashed 
line represents the endocrine pancreatic domain. Leica confocal SP5II; Zoom 2,91 x; Magnification 40x.  
 
B 
Figure 23 – Graph showing the total percentage of embryos with endocrine GFP expression 
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5.3. Zebrafish transgenesis using Z48 transposon: Endocrine pancreas 
enhancer assays 
After testing the ten selected sequences for enhancer activity in the endocrine 
pancreas, five have shown GFP expression in the endocrine pancreas, being clearly above 
the threshold set by the negative control (seq219, seq132, seq58, seq73 and seq460) (Fig.24), 
while the remaining five sequences were not able to drive expression of GFP in endocrine 
cells (seq117, seq790, seq72, seq68 and seq119) (Fig.24 and 25).  
  
 
5.3.1. Endocrine pancreas enhancers 
Seq219 (n=20), seq132 (n=20), seq58 (n=22), seq73 (n=19) and seq460 (n=20) were 
able to drive expression of GFP in pancreas endocrine cells (Fig.25 – A to E and fig 26). 
Interestingly, seq219 and seq132 did not overlap with any significant signal of H3K27ac and 
H3K4me1 present in cell lines derived from different tissues, not including the endocrine 
pancreas (ENCODE data; Fig.16). However, when analyzing by ChIP-seq results from 
endocrine islets, it is possible to detect an enrichment for H3K27ac and binding of TFs 
important for endocrine proper function. The validation of these sequences as endocrine 
enhancers by in vivo reporter assays underline the relevance and accurateness of the 
predictions for enhancer activity when using endocrine pancreatic islets. Seq58, seq73 and 
seq460 in contrast, overlap with significant signals of H3K27ac and H3K4me1 derived from 
not endocrine cell lines, together with high levels of H3K27ac and binding sites of islet 
TFBS derived from pancreas endocrine islets (Fig.16). 
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Figure 24 – Representative graph showing the total percentage of positive embryos with GFP expression 
in endocrine pancreas domain from each sequence analyzed.  
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In summary, from the sequences that have shown to be pancreatic endocrine 
enhancers, all of them have shown high signal of H3K27ac mark in pancreas endocrine cells, 
together with binding sites of TFs important for endocrine pancreas function. Presence of 
H3K27ac and H3K4me1 in cell lines not derived from endocrine cells was not required for 
at least two sequences (seq219 and seq132). This is in agreement with the observation that 
different enhancers might be active or inactive in different tissues (Remenyi et al., 2004¸  
Delic et al., 1991), suggesting that predictions based in epigenetic marks for enhancer 
activity will be more accurate when analyzing datasets from the tissue to be studied, in this 
case, the endocrine pancreas.  
Although we were able to identify five sequences with enhancer activity on the 
endocrine pancreas, it is yet to be determined the exact expression pattern that these 
enhancers drive within this tissue. To overcome this problem, the positive enhancers were 
recombined in a ZED (Zebrafish Enhancer Detector) vector  (Bessa et al., 2009), in the same 
way as Z48 recombination protocol, that has two insulators flanking the cloned sequence to 
avoid the “position effect” (Chung et al.,1993) from the activity of nearby genomic 
regulatory regions. Injected embryos are being reared to adults to generate stable transgenic 
lines containing the validated enhancers, allowing to determine a consistent expression 
pattern of GFP in the endocrine pancreas.   
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Figure 25 – Representative confocal images of seq219 (A), seq132 (B), seq58 (C), seq73 (D) and seq460 (E) 
analysis. All these five sequences showed GFP positive cells. It was used Tg:sst:mCherry as reporter line; The 
dashed line represents the endocrine pancreatic domain .Leica confocal SP5II; Zoom 2,91 x;  Magnification 40x.  
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5.3.2. Sequences with no endocrine pancreas enhancer activity 
The remaining five sequences tested for endocrine enhancer activity were not able to 
drive expression of GFP in endocrine cells, having 0% of embryos with GFP expression in 
the sst-mCherry domain, namely: seq117 (n=21), seq790 (n=20), seq72 (n=27), seq68 
(n=19) and seq119 (n=18) (Fig.27 – A-E and Fig.28). 
Seq117 shows an overlap with H3K4me1 signal but reduced H3K27ac signal derived 
from cell lines not related with endocrine pancreas (Fig.16). Regarding the data derived from 
endocrine pancreas islets, this sequence shows little overlap with H3K27ac mark, however 
binding sites for MAFB and NKX2.2 were identified. 
The remaining four sequences, seq790, seq72, seq68 and seq119, regardless of their 
signal for H3K27ac and H3K4me1 derived from not endocrine cell lines, all of them 
presented high levels of H3K27ac in endocrine cells (Fig.16). These results suggest that, 
although sequences present histone marks associated to enhancer activity, namely H3K27ac 
in cells from the tissue where enhancer activity is being evaluated, presence of H3K27ac is 
not sufficient to determine these sequences as enhancers. An alternative explanation could 
be related with the sensitiveness of our assay, since random integrations were expected to 
generate at least some noise in the negative control, described as position effect (Chung et 
al.,1993). Therefore, endocrine expression could be very restrictive in our assay, 
Figure 26 – Graph showing the total percentage of embryos expressing GFP in endocrine domain. 
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compromising the detection of very week enhancers. A third explanation for the absence of 
enhancer activity in the endocrine pancreas could be related with interspecies specific 
response, since the analyzed sequences are from the human genome. Nevertheless the model 
organism used for the reporter assays was the zebrafish, that could lack the proper 
combination of transcription factors required for the activity of some human endocrine 
enhancers (Davis et al., 2014). 
.  
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Figure 27 – Representative confocal images of seq117 (A), seq790 (B), seq72 (C), seq119 (D) and seq68(E) 
analysis. 0% of the embryos expressed GFP in the endocrine domain. In E 15% of the embryos showed GFP 
expression in the adjacent area (white arrows). It was used Tg:sst:mCherry as reporter line; The dashed line 
represents the endocrine pancreatic domain. Leica confocal SP5II; Zoom 2,91 x;  Magnification 40x.  
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5.3.3. Putative enhancers of endocrine progenitor cells 
During the course of the enhancer activity assays, we observed the presence of GFP 
positive cells in the adjacent area of the endocrine domain in assays for seq68, seq58 and 
seq73 (Fig.27- E (white arrows), Fig.28 and fig.30). One possible identity for the GFP 
labeled cells could be pancreatic progenitor cells, since they are described to be adjacent to 
the endocrine differentiated domain. Indeed, at 24hpf in zebrafish embryos, the pancreatic 
progenitor domain defined by Nkx6.1 TF do not co-localize within the domain of endocrine 
pancreatic differentiated cells, but ventrally to these hormone-producing cells (Binot et al., 
2010) (Fig.31). At 48hpf, Nkx6.1 is expressed at the base of the endocrine islet, in the ventral 
bud (Ghaye et al., 2015) (Fig.31). 
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Figure 28 – Graph showing the total percentage of embryos with GFP expression in endocrine domain in seq117, seq790, 
seq71, seq68 and seq119. 
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Figure 30 – Graph showing the total percentage embryos with GFP positive cells in endocrine pancreas adjacent 
domain from each sequence analyzed.  
 
 
Figure 29 – Representative images of the sequences with potential to be enhancers for pancreatic progenitors A 
– Seq58; B – Seq68; C – Seq73. The dashed line represents the endocrine pancreatic domain. Leica confocal 
SP5II; Zoom 2,91 x; Magnification 40x   
 
0
2
4
6
8
10
12
14
16
18
seq790 seq72 seq117 seq119 seq219 seq460 seq73 seq58 seq68
P
er
ce
n
ta
g
e 
o
f 
p
o
si
ti
v
e 
em
b
ry
o
s
Sequences
Endocrine pancreas adjacent area GFP expression
A
 
B
 
C
 
 n=20  n
=
2
1 
        GFP                         sst-mCherry                          DAPI                            MERGED 
- - -  Endocrine domain 
48hpf 
56 
 
 
 
   
 
 
 
 
 
 
 
Therefore, to define the endocrine pancreatic progenitor cells domain, regarding the 
endocrine domain, we have crossed Tg(sst:mCherry) and Tg(ins:GFP) reporter lines and we 
stained 48hpf embryos with Nkx6.1 antibody.  
 After analyzing these embryos by confocal microscopy, we found, as previously 
described (Ghaye et al., 2015), that the Nkx6.1 expression domain is ventral and adjacent to 
the endocrine differentiated islet (Fig. 32). Yet, the question still remains if sequences seq68, 
seq58 and seq73 are able to drive expression in endocrine progenitor cells, being therefore 
endocrine progenitor enhancers. Indeed, the same way that SNPs associated to T2D could 
impair the proper function of enhancers active in differentiated cells, resulting in pancreatic 
malfunction, SNPs in progenitor endocrine enhancers could affect developmental processes 
required for proper pancreas differentiation, potentially being as well a source of pancreatic 
Figure 31 – NKX6.1 pancreatic expression at 24h, regarding: A- glucagon; B- insulin; C- somatostatin; D – ghrelin. 
Scale: 20 µm. E - NKX6.1 expression at 48h in zebrafish. The endocrine domain is highlighted with white dash. Adapted 
from Binot et al., 2010 and Ghaye et al., 2015)  
 
 
E 
30µm 
Figure 32 – NKX6.1 pancreatic expression at 48hpf,in zebrafish endocrine domain.. The dashed line represents the 
pancreatic progenitor domain defined by Nkx6.1 antibody. Leica confocal SP5II; Zoom 2,91 x; Magnification 40x 
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mal function. To address this question, we have performed enhancer assays, in a sst-mCherry 
reporter line background in embryos stained with anti-Nkx6.1 at 48hpf (Fig.34, 35 and 36). 
 The negative control was obtained by the microinjection of Z48 empty vector, 
showing zero embryos with expression of GFP co-localized with anti-Nkx6.1 (Fig.33). 
 
The three sequences, seq68, seq58 and seq73 were then tested for enhancer activity 
in endocrine progenitor cells that were considered as putative progenitors enhancers by 
immunohistochemistry using the NKX6.1 antibody.  
a) Seq68 is an enhancer of endocrine pancreas progenitor 
After testing seq68 for enhancer activity, it was found that 75% of the analyzed 
embryos (n=4) presented co-expression of GFP with the anti-Nkx6.1 antibody (Fig.34 and 
36). These results indicate that the seq68 could be an enhancer of endocrine progenitor cells. 
Interestingly, when we look at the genomic landscape of seq68 (Fig.16), a NKX6.1 binding 
site overlap with this sequence, supporting the progenitor identity of the uncovered enhancer. 
 
Figure 34 – NKX6.1 pancreatic expression at 48h, in zebrafish endocrine domain. The dashed line represents the 
pancreatic progenitor domain defined by Nkx6.1 antibody Leica confocal SP5II; Zoom 2,91 x; Magnification 40x 
 
Figure 33 – Representative images of the negative control, with GFP negative cells co-localizing with NKX6.1 
positive cells. The dashed line represents the pancreatic progenitor domain defined by Nkx6.1 antibody. Leica 
confocal SP5II; Zoom 2,91 x; Magnification 40x 
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b) Seq73 and seq58 are not enhancers of endocrine progenitor cells 
 
For sequences seq58 and seq73, none of the analyzed embryos showed expression of 
GFP co-localized with Nkx6.1 (n=3) (Fig.35 and 36), suggesting that these sequences are 
not enhancers of endocrine progenitors cells. The presence of GFP positive cells outside of 
the differentiated endocrine domain could be explained by the “position effect”, already 
referred, due to the random integration of the Z48 transposon in the zebrafish genome. 
Alternatively, these sequences could be enhancers of pancreatic progenitor cells that are in 
a developmental state previous to Nkx6.1 expression and therefore, previous to endocrine 
fate determination. To access the possibility, other markers should be used, such as Pdx1 or 
Ptf1a.  A third possibility could be that these sequences are enhancers active in cells located 
nearby the endocrine domain, but not related to this tissue. 
 
 
 
 
 
 
A 
B 
Figure 35 – Representative image of the seq58 (A) and seq73(B) with GFP positive cells not co-localizing with 
NKX6.1 positive cells. The dashed line represents the pancreatic progenitor domain defined by Nkx6.1 antibody Leica 
confocal SP5II; Zoom 2,91 x; Magnification 40x 
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Figure 36 – Graph showing the total percentage embryos with GFP positive cells that colocalized with NKX6.1 
antibody in endocrine pancreas adjacent domain.  
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5.4. Impact of the T2D risk variant in uncovered enhancers 
To determine to what extent genetic variants associated T2D could impact in enhancer 
activity, we focused in three sequences, seq460, seq73 and seq132, which previously we 
determined to be endocrine pancreas enhancers We amplified by PCR exactly the same 
sequence but containing the single nucleotide variant associated to T2D, and we compared 
the ability of the three sequences to drive expression of GFP in the endocrine pancreas. 
Seq460 did not show differences in the percentage of embryos with GFP expression in the 
endocrine pancreas, when comparing to WT sequence (Fig. 37 and Table 4). However, 
sequences seq73 and seq132 showed differential enhancer activity when comparing the WT 
and T2D variants. For seq73, WT variant has shown 21% (n=19) of embryos with GFP 
expression in the endocrine pancreas, while in T2D associated variant it showed 0% (n=20) 
(Fig. 39 and Table 4).  
Table 4 – Percentage of endocrine GFP positive cells relative to WT and Risk allele.  
 
Although sequences were selected after PCR amplification for having exactly the 
same sequence with the exception of the T2D associated SNP, after analyzing in detail the 
WT seq73 sequence, we found a small deletion that is not present in the T2D associated 
variant. To completely exclude that the identified deletion could be causing the differential 
enhancer activity between the two tested sequences, we must amplify again the WT 
sequence, not containing this deletion, and perform the enhancer assay. 
Regarding seq132, we observed that WT variant has 20% (n=20) of embryos with 
GFP expression in the endocrine pancreas, while T2D associated variant showed 50% 
(n=20). These results suggest that the T2D associated variant has a gain of function, when 
comparing to the WT variant. This could be a consequence of either an increase of the 
transcriptional output of GFP or an increase of the expression pattern driven by the T2D 
variant. To distinguish both causes, as future perspectives we will repeat these assays in 
human cell lines using luciferase as a reporter gene, that will allow to assess the 
transcriptional output for each variant in a quantitative manner. To access the possibility that 
the T2D associated variant results in an increased expression pattern, we will generate stable 
Sequence WT allele  
% endocrine GFP positive cells 
 
Risk allele 
% endocrine GFP positive cells 
seq132 20% 50% 
seq73 21% 0% 
seq460 20% 20% 
60 
 
transgenic lines as described previously. To better understand how the different variants 
could be affecting the binding of TFs, therefore explaining the differences in the enhancer 
activity we have observed, we performed an in silico analysis of TFBS using JASPAR ( 
http://jaspar.genereg.net/)  (Sandelin, 2004).   
a) Seq460  
 
  
 
 
 
 
 
 
 
 
 
 
 
A 
B 
WT allele 
 
Risk allele 
T>C 
T>C 
C 
Common SNPs 
Non-described 
0
20
40
60
80
Negative control WT Risk Positive controlP
er
ce
n
ta
g
e 
o
f 
p
o
si
ti
v
e 
em
b
ry
o
s
Sequences
Endocrine pancreas GFP expression
Figure 37 – A and B - Representative image of the seq460 without the risk associated variant present (WT sequence) (A) and 
seq460 with the risk associated variant. The dashed line represents the endocrine pancreatic domain Leica confocal SP5II; 
Zoom 2,91 x; Magnification 40x C- Representative squeme of the seq460 without the risk associated variant present (WT 
sequence) and seq460 with the risk associated variant.  
 
Figure 38 – Representative graph showing the total percentage of positive embryos in WT and Risk allele associated in 
seq460. 
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b) Seq73  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
0
20
40
60
80
Negative control WT Risk Positive controlP
er
ce
n
ta
g
e 
o
f 
p
o
si
ti
v
e 
em
b
ry
o
s
Sequences
Endocrine pancreas GFP expression
WT allele 
 C deletion
Risk allele 
A 
B 
Figure 39 – A and B - Representative image of the seq73 without the risk associated variant present (WT sequence) 
(A) and seq73 with the risk associated variant. The dashed line represents the endocrine pancreatic domain .Leica 
confocal SP5II; Zoom 2,91 x; Magnification 40x C- Representative squeme of the seq73 without the risk associated 
variant present (WT sequence) and seq73 with the risk associated variant. 
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Figure 40 – Representative graph showing the total percentage of positive embryos in WT and Risk allele 
associated in seq73. 
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c) Seq132 
 
 
 
 
 
 
 
 
 
 
 
 
Common SNPs 
Figure 41 – A and B- Representative image of the seq132 without the risk associated variant present (WT sequence) and 
seq132 with the risk associated variant. The dashed line represents the endocrine pancreatic domain .Leica confocal 
SP5II; Zoom 2,91 x; Magnification 40x; C- Representative squeme of the seq132 without the risk associated variant 
present (WT sequence) and seq132 with the risk associated variant,  
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Figure 42 – Graph showing the total percentage of positive embryos in WT and Risk allele associated in seq132.. 
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d) JASPAR analysis – TFBS prediction   
Table 5 – JASPAR analysis from the seq132, where the only differential SNP in the two sequences is the risk and WT allele. 
In grey: TFBS motif; In green: WT allele; In red: Risk allele; # Complementary chain 
 
The table 5 shows a selected group of TFs that bind differentially to WT sequence 
and T2D risk variants, in the seq132 (See supplementary data – table 1). This group of TFs 
was selected by their potential function in the pancreas. We observed that the WT variant has 
a predicted increased affinity to bind TF 3 (TCF3), NEUROD1, (Recombination Signal 
Binding Protein for Immunoglobulin Kappa J Region) (RBPJ) and ASCL1, while the T2D 
Risk variant lose the affinity to bind these TFs, gaining affinity to bind PAX2 and Specificity 
protein 1 (SP1). In addition, although not being an example of gain or loss, the binding site 
of paired homeobox 5 (PAX5) is predicted to be more stable in the T2D risk variant than in 
the WT variant. These TFs have different characteristics as following: 
TCF3 is a TF related to neuronal differentiation. More importantly, it can bind to 
short regulatory DNA sequences in INSULIN gene, acting as a transcriptional activator 
(Uniprot dataset, 2018), however, its role is not yet fully understood in endocrine pancreas 
function (Cristancho et al., 2011).  
   
   
   
   
TF Allele Affinity score (0-low; 1 
– high) 
Sequence 
TCF3 WT 0.952250390723 CCGAACCACTTGGCTGTCCCAGCTGGCTGCTGTTGATAAAG 
TCF3 Risk 0 CCGAACCACTTGGCTGTCCCGGCTGGCTGCTGTTGATAAAG 
PAX5 WT 0.858808679485 CTTTATCAACAGCAGCCAGCTGGGACAGCCAAGTGGTTCGG 
PAX5 Risk 0.888219182514 CTTTATCAACAGCAGCCAGCCGGGACAGCCAAGTGGTTCGG 
PAX2 WT 0 CCGAACCACTTGGCTGTCCCAGCTGGCTGCTGTTGATAAAG 
PAX2 Risk 0.856667239833 CCGAACCACTTGGCTGTCCCGGCTGGCTGCTGTTGATAAAG 
NEUROD1 WT 0.872118037809 CTTTATCAACAGCAGCCAGCTGGGACAGCCAAGTGGTTCGG 
NEUROD1 Risk 0 CTTTATCAACAGCAGCCAGCCGGGACAGCCAAGTGGTTCGG 
RBPJ WT 0.855183014761 CTTTATCAACAGCAGCCAGCTGGGACAGCCAAGTGGTTCGG 
RBPJ Risk 0 CTTTATCAACAGCAGCCAGCCGGGACAGCCAAGTGGTTCGG 
ASCL1 WT 0.840690936086 CTTTATCAACAGCAGCCAGCTGGGACAGCCAAGTGGTTCGG 
ASCL1 Risk 0 CTTTATCAACAGCAGCCAGCCGGGACAGCCAAGTGGTTCGG 
SP1 WT 0 CCGAACCACTTGGCTGTCCCAGCTGGCTGCTGTTGATAAAG 
SP1 Risk 0.801216594697 CCGAACCACTTGGCTGTCCCGGCTGGCTGCTGTTGATAAAG 
# 
# 
# 
# 
# 
# 
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  PAX2, as referred before, has a key role in pancreas development, since it controls 
the relative proportion of endocrine and exocrine pancreas tissues (Zaiko et al., 2004). In 
addition, since this transcription factor works as an activator, the presence of its binding site 
in the T2D risk variant could explain the gain of function observed in this variant (Fig.41 
and 42).  
NEUROD1 regulates INSULIN gene expression is important for pancreas cell fate 
determination (Itkin-Ansari et al., 2005) and the absence of this TF may result in T2D 
(RefSeq, Jul, 2008).  
RBPJ have been associated to Notch signaling (Lake et al., 2014), a pathway that 
works as a key regulator of pancreas embryonic development and homeostasis  (Kim et 
al.,2010). This TF is not functioning as activator in the sequence WT. Interestingly, RBPJ 
can work as a transcriptional repressor when it is not binding to Notch proteins. RBPJ 
repressive activity could explain the decreased enhancer activity observed associated to the 
WT variant  (Kim et al.,2010).  
ASCL1 controls neuronal differentiation, being described as a transcriptional 
activator.  The only association with diabetes resides in the consequences of high glucose 
levels, that alters the expression of (Fu et al.,2006)..  
SP1 is a zinc finger TF. Interestingly, post-translational modifications such as 
phosphorylation, acetylation and glycosylation significantly affect the activity of this 
protein, which can operate as an activator or a repressor of transcription (Solomon et al., 
2008) (Pan et al, 2001).  
In summary, a single nucleotide modification has the potential to change the binding 
of several TFs that eventually might impact in the transcriptional output of the enhancer. 
This should be further addressed by performing ChIP-PCR in the corresponding sequences, 
to determine which of the proposed TFs are effectively binding to the different variants, 
allowing us to build a better molecular explanation for the differential enhancer activity 
observed when comparing the WT and T2D risk associated variants. 
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e) A new single nucleotide variant can disrupt the enhancer activity in seq132 
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For the case of seq132, we tested five different sequences for enhancer activity in the 
endocrine pancreas. Each of these sequences, A to E (Fig 43), were exactly the same among 
each other, with the exception for the SNPs annotated in figure 43 - F. Interestingly, when 
testing sequences C and D, that only vary in the WT and T2D risk allele respectively, it was 
observed that DNA C (WT variant) presented a decreased percentage of embryos with GFP 
expression in the endocrine pancreas (20%, n=20) when comparing to DNA D (T2D risk 
variant; 50%, n=20; Fig.43). When testing a new DNA (DNA B) containing a new sequence 
that contains an extra single nucleotide modification, not described as a common SNP, we 
observed that the enhancer activity was completely lost (0%, n=20). To better understand 
molecularly what could be causing the ablation of the enhancer by the single nucleotide 
modification present in DNA B, we explored differentially putative binding sites of TFs 
using JASPAR, as previously described, analyzing the DNA A against DNA B (Table 6). 
Strikingly, the in silico prediction showed a putative binding site for PDX1 TF, whose 
binding site is lost by the presence of the single nucleotide modification present in DNA B 
(See supplementary data – table 2).  
 
 
 
 
Figure 43 – A-E - Representative image of the different sequences of seq132 with risk allele. The sequence B didn’t show 
GFP expression in endocrine domain. The dashed line represents the endocrine pancreatic domain. Leica confocal SP5II; 
Zoom 2,91x; Magnification 40x  F – Graphic squeme of the sequences correspondent to the different DNAs, including the 
present SNPs. G – Representative graph showing the total percentage and the number of analyzed embryos in the different 
sequences injected.    
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Table6 - JASPAR analysis from the seq132 – DNA B, showing a putative binding site for PDX1. In grey: TFBS motif; In 
green: WT allele; In purple: New variant; # Complementary chain 
 
 As referred before, PDX1 is an important TF in pancreas development, β-cell 
differentiation and function. The presence of a single modification disrupted the putative 
binding site of PDX1, which could be causing the disruption of the enhancer activity of the 
sequence. 
Apart from the differentially affinity for the binding of PDX1 in DNA B, other 
transcription factors were also identified, namely:      
 Homeobox 3 (HOXB3), homeobox 2 HOXB2 and lim homeobox 9(LHX9) are 
homeobox TF directly related to development. Variants that allow to create new binding 
sites for these 3 homeobox TF are associated to an  increase in NAD-dependent deacetylase 
sirtuin 2 (SIRT2)  promoter activity in beta cells, contributing to T2D through diverse 
pathways as a risk factor. (Liu et al.,2018). 
 SRY-Box 17 (SOX17) is a key transcriptional regulator that can act by regulating 
other transcription factors including HNF1β and FOXA2, which are known to regulate 
postnatal β-cell function. SOX17 has a critical role in regulating insulin trafficking and 
secretion (Jonatan et al., 2014). 
TF Seque
nce 
Affinity score (0-
low;1 - high) 
Sequence 
PDX1 A 0.965432863673 GAGTCATTTTTTAGCAGCCTAATGTGTTATCCTTGGCCTGA 
PDX1 B 0 GAGTCATTTTTTAGCAGCCCAATGTGTTATCCTTGGCCTGA 
HOXB3 A 0.925700528633 TCAGGCCAAGGATAACACATTAGGCTGCTAAAAAATGACTC 
HOXB3 B 0 TCAGGCCAAGGATAACACATTGGGCTGCTAAAAAATGACTC 
HOXB2 A 0.903052079754 TCAGGCCAAGGATAACACATTAGGCTGCTAAAAAATGACTC 
HOXB2 B 0 TCAGGCCAAGGATAACACATTGGGCTGCTAAAAAATGACTC 
LHX9 A 0.864562264679 TCAGGCCAAGGATAACACATTAGGCTGCTAAAAAATGACTC 
LHX9 B 0 TCAGGCCAAGGATAACACATTGGGCTGCTAAAAAATGACTC 
SOX17 A 0.86255929928 TCAGGCCAAGGATAACACATTAGGCTGCTAAAAAATGACTC 
SOX17 B 0 TCAGGCCAAGGATAACACATTGGGCTGCTAAAAAATGACTC 
GSC A 0.852756075706 GAGTCATTTTTTAGCAGCCTAATGTGTTATCCTTGGCCTGA 
GSC B 0 GAGTCATTTTTTAGCAGCCCAATGTGTTATCCTTGGCCTGA 
PRRX2 A 0.843137571821 TCAGGCCAAGGATAACACATTAGGCTGCTAAAAAATGACTC 
PRRX2 B 0 TCAGGCCAAGGATAACACATTGGGCTGCTAAAAAATGACTC 
SOX13 A 0 TCAGGCCAAGGATAACACATTAGGCTGCTAAAAAATGACTC 
SOX13 B 0.829650813997 TCAGGCCAAGGATAACACATTGGGCTGCTAAAAAATGACTC 
# 
# 
# 
# 
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Paired mesoderm homeobox protein 2 (PRRX2) is a TF that is involved in adipocyte 
differentiation. An impaired adipogenesis may underlie the development of diabetes (Du et 
al., 2013).  
Because PDX1 has the highest relative score and because of its very well-known 
function in the pancreas, this is the best candidate to explain the loss of the enhancer activity 
in DNA B. In addition, looking to ChIP-seq data from endocrine pancreas (Pasquali et al, 
2014), we are able to identify a clear enrichment for the binding of PDX1 in this sequence, 
further supporting the in silico prediction for the binding of PDX1 (Figure 44). Further 
studies of this new single nucleotide modification may give interesting insights about new 
genetic modifications that might impact in T2D. For this, it would be interesting to: 1) 
analyze if this single nucleotide modification is present in the human population and with 
which frequency, 2) determine is this single nucleotide modification is more or less prevalent 
in T2D patients. 
 
 
 
 
 
     
 
 
 
The interesting results obtained by the analysis of different variants of seq132 lead 
us to further explore this sequence. We hypothesize that seq132 might have different 
topological regions that confer the enhancer activity. To evaluate these topological regions, 
we have fragmented the sequence and tested the different fragments for enhancer activity in 
endocrine pancreas (Fig.45). Curiously, fragments 1 (9,8%; n=43), 2 (6,5%; n=31) and 1 
extended (10%; n=30) showed a decreased enhancer activity when comparing to the total 
SLC30A8  
PDX1 
H3Kac27 
H3K4Me1 
Figure 44 – A- Resulted prediction by JASPAR analysis, showing the new variant (*) located in PDX1 binding site. B- ChIP 
analysis including the newly discovered variant, overlapping with acetylation and methylation signals, as PDX1 signal.  
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fragment (20%; n=30; Fig45). Nevertheless, these results demonstrate that these fragments 
can work independently of each other. In addition, it was surprising to find that fragment 2 
was able to drive enhancer activity on its own. This is surprising due to previous experiments 
with the total fragment with the mutated putative binding site of PDX1, that suggested that 
this binding site, present in fragment 1, is necessary to the activity of the total fragment. This 
hypothesis is contradicted by the results obtained by fragment 2, that do not contain the 
binding site of PDX1. Therefore, the putative binding site of PDX1 should not be necessary 
for the activity of the enhancer. As an alternative explanation that is coherent with all the 
presented results, is that the single nucleotide modification might ablate the putative binding 
of PDX1, generating another putative binding of a transcriptional repressor, which could 
explain the loss of the enhancer activity observed in DNA B.     
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Figure 45 – A- Graphic squeme of the total sequence and the fragments. B-D – Representative confocal images of 
the different fragments (B – fragment 1; C – Fragment 2; D – Extended fragment 1). The dashed line represents the 
endocrine pancreatic domain .Leica confocal SP5II; Zoom 2,91x; Magnification 40x. E– Representative graph 
showing the total percentage in the different fragments and in total sequence.    
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IV. General conclusions and future perspectives 
The transcriptional regulatory mechanism of gene expression is required for a proper 
cell and tissue function (Alberts, 2002). In this sense, a disruption in this mechanism might 
result in several diseases (Kleinjan & Coutinho, 2009), such as T2D. The elements that 
control this transcriptional mechanism are located mostly in non-coding genome and are 
named as CREs. Among these elements, there are endocrine pancreas enhancers that can 
serve as target site for TFBS (Pennacchio et al., 2013) and might be important for endocrine 
pancreas islets function and development. Enhancers can act in long range, by chromatin 
loops, allowing the interaction between the TF with the promoters of the enhancer target 
gene (Mora et al., 2015).  
The progressive findings in enhancers function and associated fingerprints allow 
their identification in the genome. This identification and the study of such regulatory 
regions have become important due to the association of variations in enhancers to 
transcriptional dysregulation of genes, phenotypic alterations and disease (Maston et al., 
2006; Pennacchio et al., 2013).            
Currently, several studies have shown that enhancers are enriched in SNPs associated 
to several diseases (Dunham et al., 2012; Hindorff et al., 2009; Maurano et al., 2012; Trynka 
et al., 2013), such as T2D (Mohlke & Boehnke, 2015; Pasquali et al., 2014). The study of 
putative enhancers that contains T2D associated SNPs is poorly known due to the lack of 
investigations and validations in vivo. 
The main hypothesis of this work was that SNPs might impair TFBS resulting in a 
modulation of enhancer activity in endocrine islets impacting in their function, having the 
potential to contribute for disease susceptibility. The first question that we have addressed 
in this work was to understand to what extend sequences that overlap with SNPs associated 
to T2D could be endocrine enhancers. We selected 10 of such sequences based on epigenetic 
marks of enhancer activity and TFBS. Then we tested if these 10 sequences were or not 
pancreas endocrine enhancers, having found that this was the case for 5 out of the 10 tested 
sequences. Then, we wanted to analyze the impact of the presence of the T2D associated 
variant in enhancer activity. For one sequence, we were able to demonstrate the impact of a 
T2D associated variant in enhancer activity by transgenesis assays, supporting the 
observations by analyzing in silico differentially affinities for the binding of TFs. 
72 
 
Furthermore, we were capable to discover a new single nucleotide modification, located in 
a PDX1 binding site, that ablated the enhancer activity of one of the tested sequences.      
Overall, this project helped us to understand the importance of non-coding regions in 
transcriptional regulation and the impact in these machinery by the presence of SNPs in T2D.  
As future steps, we will aim to continue studying the impact of the associated SNPs 
to T2D and other putative SNPs not described yet, identify the enhancer`s target genes by 
4C and test the enhancer activity in human β-cell lines. 
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VI. Supplementary data 
Table 1 – JASPAR complementary analysis. From the 719 matrices available from vertebrates in JASPAR database, 393 matrices were identified 
associated to WT/Risk seq132. Then, these results were refined by eliminating all the TFBS motifs that not included the WT7Risk locus, resulting 
in the table below. (A). Regarding the risk associated variant sequence and based on the relative scores obtained, it was created a resume table 
with the number of TFs that had differential affinity with the risk sequence, as the gain/loss of binding (B). 
A) 
Name Score Relative 
score 
Sequence 
ID 
Start End Strand Predicted sequence 
PAX5 13,7514 0,888219 risk 11 29 + AACAGCAGCCAGCCGGGAC 
PAX5 11,2341 0,858809 wt 11 29 + AACAGCAGCCAGCTGGGAC 
Tcfcp2l1 6,51404 0,826334 wt 13 26 - CCAGCTGGCTGCTG 
Tcfcp2l1 5,41685 0,810356 risk 13 26 - CCGGCTGGCTGCTG 
SMAD2::SMAD3::SMAD4 8,42222 0,822335 risk 14 26 - CCGGCTGGCTGCT 
PAX1 8,67591 0,844119 risk 14 30 - TGTCCCGGCTGGCTGCT 
PAX9 8,50939 0,831403 risk 14 30 - TGTCCCGGCTGGCTGCT 
Myod1 8,713 0,90222 wt 15 27 - CCCAGCTGGCTGC 
THAP1 5,21293 0,827175 risk 16 24 + CAGCCAGCC 
THAP1 5,13392 0,824757 wt 16 24 + CAGCCAGCT 
Hand1::Tcf3 6,75256 0,822532 risk 16 25 - CGGCTGGCTG 
Hand1::Tcf3 6,22582 0,807013 wt 16 25 - CAGCTGGCTG 
TAL1::TCF3 7,37002 0,805375 wt 16 27 + CAGCCAGCTGGG 
ASCL1 8,27687 0,840691 wt 16 28 + CAGCCAGCTGGGA 
NEUROD1 8,88346 0,855731 wt 16 28 - TCCCAGCTGGCTG 
TWIST1 8,03054 0,845006 wt 16 28 + CAGCCAGCTGGGA 
ZBTB18 4,742 0,812299 wt 16 28 + CAGCCAGCTGGGA 
Myb 5,54864 0,839174 wt 17 26 - CCAGCTGGCT 
SP1 6,14518 0,801217 risk 17 26 - CCGGCTGGCT 
Myog 6,4557 0,880515 wt 17 27 - CCCAGCTGGCT 
Tcf12 5,5395 0,85822 wt 17 27 - CCCAGCTGGCT 
Tcf3 12,555 0,95225 wt 17 27 - CCCAGCTGGCT 
Tcf3 3,5146 0,831997 risk 17 27 - CCCGGCTGGCT 
USF1 3,66816 0,821319 wt 17 27 - CCCAGCTGGCT 
ZEB1 5,18344 0,832761 wt 17 27 - CCCAGCTGGCT 
TFAP2A(var.2) 3,40101 0,805747 risk 17 28 - TCCCGGCTGGCT 
ASCL1 7,47043 0,827144 wt 17 29 - GTCCCAGCTGGCT 
NEUROD1 9,74202 0,872118 wt 17 29 + AGCCAGCTGGGAC 
TWIST1 7,92463 0,842924 wt 17 29 - GTCCCAGCTGGCT 
Atoh1 13,7404 0,995554 wt 18 25 - CAGCTGGC 
Atoh1 5,27962 0,867004 risk 18 25 - CGGCTGGC 
TFAP2A 6,77176 0,881869 risk 18 26 + GCCAGCCGG 
TFAP2A 5,558 0,842262 wt 18 26 + GCCAGCTGG 
Ascl2 7,13469 0,823026 wt 18 27 - CCCAGCTGGC 
Ascl2 6,17312 0,803928 wt 18 27 + GCCAGCTGGG 
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Atoh1 4,88617 0,814033 wt 18 27 - CCCAGCTGGC 
Atoh1 4,69235 0,810347 wt 18 27 + GCCAGCTGGG 
FIGLA 8,92208 0,893885 wt 18 27 - CCCAGCTGGC 
FIGLA 8,35565 0,882604 wt 18 27 + GCCAGCTGGG 
ID4 6,01732 0,840488 wt 18 27 - CCCAGCTGGC 
ID4 5,08781 0,822668 wt 18 27 + GCCAGCTGGG 
MYB 3,78195 0,808536 wt 18 27 - CCCAGCTGGC 
Neurog1 6,37768 0,850801 wt 18 27 + GCCAGCTGGG 
Neurog1 5,56536 0,831939 wt 18 27 - CCCAGCTGGC 
NHLH1 7,53104 0,842895 wt 18 27 - CCCAGCTGGC 
NHLH1 5,58268 0,809935 wt 18 27 + GCCAGCTGGG 
TCF3 8,0431 0,904707 wt 18 27 - CCCAGCTGGC 
TCF3 7,57315 0,896806 wt 18 27 + GCCAGCTGGG 
TCF4 8,45918 0,916803 wt 18 27 - CCCAGCTGGC 
TCF4 6,52403 0,887207 wt 18 27 + GCCAGCTGGG 
TFAP4 7,49354 0,848832 wt 18 27 - CCCAGCTGGC 
TFAP4 6,30787 0,829728 wt 18 27 + GCCAGCTGGG 
EBF1 0,968359 0,818794 wt 18 28 + GCCAGCTGGGA 
Myog 8,92548 0,913604 wt 18 28 + GCCAGCTGGGA 
Tcf12 7,86887 0,89074 wt 18 28 + GCCAGCTGGGA 
Tcf3 5,84578 0,863006 wt 18 28 + GCCAGCTGGGA 
ZEB1 4,54018 0,820895 wt 18 28 + GCCAGCTGGGA 
Myod1 7,37601 0,885033 wt 18 30 + GCCAGCTGGGACA 
Bhlha15 7,74005 0,890508 wt 19 26 + CCAGCTGG 
Bhlha15 7,74005 0,890508 wt 19 26 - CCAGCTGG 
Tcfcp2l1 7,01468 0,833625 wt 19 32 - GCTGTCCCAGCTGG 
Tcfcp2l1 5,30934 0,808791 risk 19 32 - GCTGTCCCGGCTGG 
Tcfcp2l1 5,10924 0,805877 wt 19 32 + CCAGCTGGGACAGC 
ZEB1 5,26234 0,841225 wt 20 25 + CAGCTG 
ZEB1 5,26234 0,841225 wt 20 25 - CAGCTG 
Atoh1 5,96758 0,877457 wt 20 27 + CAGCTGGG 
STAT3 1,32493 0,813606 wt 20 30 + CAGCTGGGACA 
STAT3 0,586987 0,804666 risk 20 30 + CAGCCGGGACA 
Hic1 6,92242 0,857816 wt 21 29 - GTCCCAGCT 
HIC2 5,81832 0,858157 wt 21 29 - GTCCCAGCT 
TFDP1 6,17637 0,803288 risk 21 31 + AGCCGGGACAG 
RBPJ 6,29924 0,855183 wt 22 31 + GCTGGGACAG 
MZF1 5,26193 0,825553 wt 23 28 + CTGGGA 
Pax2 5,41577 0,856667 risk 23 30 - TGTCCCGG 
MEIS1 4,4281 0,874519 wt 25 31 + GGGACAG 
MEIS1 4,4281 0,874519 risk 25 31 + GGGACAG 
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B) 
Binding classification Nr. of TFs 
Gain of binding 7 
Loss of binding 49 
Equally binding 1 
Differential affinity 9 
More affinity with WT 9 
More affinity with Risk 0 
Total 66 
 
Table 2– JASPAR complementary analysis. From the 719 matrices available from vertebrates in JASPAR database, 395 matrices were identified 
associated to the new variant locus of seq132 (Sequence A and B). Then, these results were refined by eliminating all the TFBS motifs that not 
included the new variant locus, resulting in the table below. (A). Regarding the new variant sequence and based on the relative scores obtained, 
it was created a resume table with the number of TFs that had differential affinity with the risk sequence, as the gain/loss of binding (B). 
A)    
Barhl1 5,78458 0,857933 A 15 24 - CCTAATGTGT 
BARX1 7,03086 0,908928 A 16 23 + CACATTAG 
BSX 7,087 0,914781 A 16 23 + CACATTAG 
Dlx1 5,79912 0,850705 A 15 24 + ACACATTAGG 
Dlx1 4,44089 0,816334 A 15 24 - CCTAATGTGT 
Dlx3 4,19829 0,806643 A 16 23 + CACATTAG 
Dlx4 3,95614 0,812796 A 16 23 + CACATTAG 
DLX6 3,83269 0,812547 A 16 23 + CACATTAG 
EMX1 6,84 0,855305 A 15 24 - CCTAATGTGT 
EMX2 4,97426 0,854383 A 15 24 + ACACATTAGG 
EN1 3,52958 0,818276 A 16 23 - CTAATGTG 
EN1 3,46397 0,81685 A 16 23 + CACATTAG 
EN1 3,29767 0,813236 B 16 23 - CCAATGTG 
EN2 3,54739 0,802258 A 15 24 + ACACATTAGG 
ESX1 4,37769 0,804111 A 15 24 + ACACATTAGG 
EVX1 6,87292 0,87899 A 15 24 + ACACATTAGG 
EVX1 3,46919 0,801535 B 15 24 + ACACATTGGG 
EVX2 6,71104 0,879358 A 15 24 + ACACATTAGG 
GBX2 2,87318 0,800436 A 15 24 + ACACATTAGG 
GSC 6,79121 0,852756 A 15 24 - CCTAATGTGT 
GSC2 6,44675 0,84727 A 15 24 - CCTAATGTGT 
GSX1 6,43485 0,868316 A 15 24 + ACACATTAGG 
GSX2 6,33842 0,854244 A 15 24 + ACACATTAGG 
HLTF 5,99807 0,891561 B 15 24 + ACACATTGGG 
HOXA2 7,13602 0,891768 A 15 24 + ACACATTAGG 
HOXB2 7,39411 0,903052 A 15 24 + ACACATTAGG 
HOXB3 8,23982 0,925701 A 15 24 + ACACATTAGG 
LBX2 5,10636 0,81309 A 15 24 + ACACATTAGG 
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LHX2 4,13569 0,83228 A 15 24 + ACACATTAGG 
Lhx4 4,50603 0,827991 A 16 23 + CACATTAG 
LHX9 5,96023 0,864562 A 16 23 + CACATTAG 
LHX9 4,35348 0,820612 B 16 23 - CCAATGTG 
LHX9 4,24138 0,817546 A 16 23 - CTAATGTG 
MAX 3,37815 0,822678 B 13 22 + TAACACATTG 
MEOX1 3,98444 0,807705 A 15 24 + ACACATTAGG 
MEOX2 4,64834 0,807508 A 15 24 + ACACATTAGG 
MIXL1 4,19813 0,814476 A 15 24 + ACACATTAGG 
MSX1 4,10645 0,811173 A 16 23 + CACATTAG 
Myb 5,49038 0,838215 A 22 31 - TTAGCAGCCT 
NEUROD
2 
3,71909 0,825543 B 14 23 + AACACATTGG 
Neurog1 5,87923 0,839227 B 14 23 - CCAATGTGTT 
NFIC 4,18303 0,815303 B 21 26 + TGGGCT 
NFIX 4,44073 0,850052 B 20 28 - GCAGCCCAA 
NKX6-2 4,52884 0,825328 A 16 23 + CACATTAG 
Nobox 5,55365 0,808411 A 15 22 - TAATGTGT 
NOTO 9,595 0,937407 A 15 24 + ACACATTAGG 
NOTO 6,23956 0,87807 B 15 24 + ACACATTGGG 
NOTO 3,03128 0,821335 A 15 24 - CCTAATGTGT 
OTX1 4,08116 0,838898 A 16 23 - CTAATGTG 
OTX2 4,27851 0,835533 A 16 23 - CTAATGTG 
PDX1 6,65422 0,897612 A 16 23 + CACATTAG 
Pdx1 8,72988 0,965433 A 18 23 - CTAATG 
POU6F2 6,11604 0,821316 A 14 23 + AACACATTAG 
PRRX1 4,10662 0,80646 A 16 23 + CACATTAG 
Prrx2 5,34257 0,843138 A 18 22 + CATTA 
Prrx2 4,75481 0,811404 A 16 23 + CACATTAG 
RAX2 4,7258 0,819227 A 16 23 + CACATTAG 
RUNX1 6,66952 0,802185 A 12 22 - TAATGTGTTAT 
SHOX 5,6106 0,833115 A 16 23 - CTAATGTG 
Shox2 3,7445 0,820281 A 16 23 + CACATTAG 
Shox2 3,08584 0,805505 A 16 23 - CTAATGTG 
Shox2 3,06607 0,805062 B 16 23 - CCAATGTG 
SOX10 4,67125 0,81183 B 17 22 - CAATGT 
SOX10 5,27395 0,838587 B 18 23 + CATTGG 
SOX13 6,61122 0,829651 B 15 25 + ACACATTGGGC 
SOX15 4,98147 0,809948 A 14 23 - CTAATGTGTT 
SOX15 4,70413 0,803721 B 14 23 - CCAATGTGTT 
Sox17 7,40552 0,862559 B 16 24 + CACATTGGG 
Sox17 6,0738 0,819538 B 16 24 - CCCAATGTG 
Sox2 5,09819 0,842691 B 16 23 - CCAATGTG 
Sox3 3,50202 0,817477 B 14 23 - CCAATGTGTT 
Sox6 5,08245 0,81139 B 14 23 - CCAATGTGTT 
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TFEC 5,78176 0,806881 A 14 23 + AACACATTAG 
THAP1 4,49031 0,805059 B 19 27 - CAGCCCAAT 
Twist2 5,20841 0,80929 B 14 23 - CCAATGTGTT 
UNCX 4,38507 0,807021 A 16 23 + CACATTAG 
VAX1 5,17372 0,826976 A 16 23 - CTAATGTG 
VAX1 4,75703 0,815147 A 16 23 + CACATTAG 
VAX2 4,94313 0,824748 A 16 23 + CACATTAG 
VAX2 4,68486 0,817921 A 16 23 - CTAATGTG 
VENTX 7,26487 0,886751 A 15 23 + ACACATTAG 
VSX1 4,72882 0,801896 A 16 23 - CTAATGTG 
 
B) 
Binding classification Nr. of TFs 
Gain of function 54 
Loss of function 16 
Differential affinity 6 
More affinity with A 5 
More affinity with B 1 
Total 76 
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